https://trial.medpath.com/news/eli-lilly-and-alchemab-forge-415m-partnership-for-novel-als-antibody-therapy 2025-05-06T14:03:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-and-alchemab-forge-415m-partnership-for-novel-als-antibody-therapy 2025-05-06T14:03:48+00:00 hourly 0.9 https://trial.medpath.com/news/verona-pharma-to-present-comprehensive-analyses-of-ohtuvayre-in-copd-at-ats-2025 2025-05-06T13:35:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/verona-pharma-to-present-comprehensive-analyses-of-ohtuvayre-in-copd-at-ats-2025 2025-05-06T13:35:19+00:00 hourly 0.9 https://trial.medpath.com/news/paradigm-shift-in-c3g-treatment-new-clinical-criteria-for-therapy-escalation-and-emerging-complement-inhibitors 2025-05-06T13:34:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/paradigm-shift-in-c3g-treatment-new-clinical-criteria-for-therapy-escalation-and-emerging-complement-inhibitors 2025-05-06T13:34:06+00:00 hourly 0.9 https://trial.medpath.com/news/livekidney-initiates-phase-i-iia-trial-of-novel-cell-therapy-lk-sc001-for-lupus-nephritis 2025-05-06T13:34:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/livekidney-initiates-phase-i-iia-trial-of-novel-cell-therapy-lk-sc001-for-lupus-nephritis 2025-05-06T13:34:04+00:00 hourly 0.9 https://trial.medpath.com/news/safe-life-expands-european-aed-market-presence-through-swiss-acquisition-of-resqshock 2025-05-06T11:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/safe-life-expands-european-aed-market-presence-through-swiss-acquisition-of-resqshock 2025-05-06T11:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/rapidpulse-initiates-patient-enrollment-in-pivotal-ide-study-for-novel-ischemic-stroke-treatment 2025-05-06T11:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rapidpulse-initiates-patient-enrollment-in-pivotal-ide-study-for-novel-ischemic-stroke-treatment 2025-05-06T11:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/khondrion-secures-eur5-million-government-credit-to-advance-phase-3-trial-for-rare-mitochondrial-disease 2025-05-06T10:34:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/khondrion-secures-eur5-million-government-credit-to-advance-phase-3-trial-for-rare-mitochondrial-disease 2025-05-06T10:34:41+00:00 hourly 0.9 https://trial.medpath.com/news/crispr-based-immunotherapy-achieves-complete-remission-in-terminal-colon-cancer-patient 2025-05-06T10:34:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crispr-based-immunotherapy-achieves-complete-remission-in-terminal-colon-cancer-patient 2025-05-06T10:34:39+00:00 hourly 0.9 https://trial.medpath.com/news/blocking-nitrosylation-a-breakthrough-strategy-for-treating-aggressive-nras-melanoma 2025-05-06T10:34:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blocking-nitrosylation-a-breakthrough-strategy-for-treating-aggressive-nras-melanoma 2025-05-06T10:34:38+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-givinostat-for-polycythemia-vera-treatment 2025-05-06T10:34:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-fast-track-designation-to-givinostat-for-polycythemia-vera-treatment 2025-05-06T10:34:32+00:00 hourly 0.9 https://trial.medpath.com/news/shilpa-medicare-s-bengaluru-facility-receives-ema-gmp-certification-for-advanced-drug-delivery-systems 2025-05-06T10:34:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shilpa-medicare-s-bengaluru-facility-receives-ema-gmp-certification-for-advanced-drug-delivery-systems 2025-05-06T10:34:12+00:00 hourly 0.9 https://trial.medpath.com/news/biofrontera-s-ameluz-secures-patent-extension-to-2043-targets-5-7b-acne-market 2025-05-06T10:34:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biofrontera-s-ameluz-secures-patent-extension-to-2043-targets-5-7b-acne-market 2025-05-06T10:34:04+00:00 hourly 0.9 https://trial.medpath.com/news/novaremed-completes-enrollment-in-nih-sponsored-phase-2b-trial-of-non-opioid-nrd-e1-for-diabetic-neuropathy-pain 2025-05-06T10:33:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novaremed-completes-enrollment-in-nih-sponsored-phase-2b-trial-of-non-opioid-nrd-e1-for-diabetic-neuropathy-pain 2025-05-06T10:33:56+00:00 hourly 0.9 https://trial.medpath.com/news/hovione-and-firstgene-partner-to-develop-novel-gene-therapy-for-liver-cancer 2025-05-06T09:06:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hovione-and-firstgene-partner-to-develop-novel-gene-therapy-for-liver-cancer 2025-05-06T09:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/viralgen-and-trogenix-partner-to-accelerate-aav-gene-therapy-for-glioblastoma 2025-05-06T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/viralgen-and-trogenix-partner-to-accelerate-aav-gene-therapy-for-glioblastoma 2025-05-06T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/dianthus-therapeutics-completes-enrollment-in-phase-2-magic-trial-for-generalized-myasthenia-gravis-treatment 2025-05-06T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dianthus-therapeutics-completes-enrollment-in-phase-2-magic-trial-for-generalized-myasthenia-gravis-treatment 2025-05-06T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/datavant-and-boehringer-ingelheim-expand-real-world-evidence-partnership-across-75-clinical-trials 2025-05-06T08:04:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/datavant-and-boehringer-ingelheim-expand-real-world-evidence-partnership-across-75-clinical-trials 2025-05-06T08:04:04+00:00 hourly 0.9 https://trial.medpath.com/news/safeheal-secures-eur35-million-in-series-c-funding-to-advance-colovac-device-for-colorectal-surgery 2025-05-06T08:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/safeheal-secures-eur35-million-in-series-c-funding-to-advance-colovac-device-for-colorectal-surgery 2025-05-06T08:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/catheter-precision-acquires-cardionomic-s-heart-failure-technology-for-novel-neuromodulation-therapy 2025-05-06T08:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/catheter-precision-acquires-cardionomic-s-heart-failure-technology-for-novel-neuromodulation-therapy 2025-05-06T08:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/vertex-pharmaceuticals-reports-strong-q1-2025-results-with-8-revenue-growth-projection-amid-pipeline-advancements 2025-05-06T07:34:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vertex-pharmaceuticals-reports-strong-q1-2025-results-with-8-revenue-growth-projection-amid-pipeline-advancements 2025-05-06T07:34:36+00:00 hourly 0.9 https://trial.medpath.com/news/transpire-bio-expands-r-d-and-manufacturing-footprint-in-florida-to-support-inhaled-therapeutics-pipeline 2025-05-06T06:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/transpire-bio-expands-r-d-and-manufacturing-footprint-in-florida-to-support-inhaled-therapeutics-pipeline 2025-05-06T06:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/route-92-medical-wins-patent-litigation-settlement-q-apel-permanently-removes-competing-neurovascular-product 2025-05-06T06:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/route-92-medical-wins-patent-litigation-settlement-q-apel-permanently-removes-competing-neurovascular-product 2025-05-06T06:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/novavax-and-takeda-strengthen-partnership-with-improved-terms-for-covid-19-vaccine-in-japan 2025-05-06T05:37:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novavax-and-takeda-strengthen-partnership-with-improved-terms-for-covid-19-vaccine-in-japan 2025-05-06T05:37:19+00:00 hourly 0.9 https://trial.medpath.com/news/fda-will-ask-outside-experts-to-review-capricor-s-therapy-for-duchenne-muscular-dystrophy 2025-05-06T05:36:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-will-ask-outside-experts-to-review-capricor-s-therapy-for-duchenne-muscular-dystrophy 2025-05-06T05:36:59+00:00 hourly 0.9 https://trial.medpath.com/news/renovorx-secures-new-u-s-patent-for-tamp-therapy-platform-strengthening-ip-portfolio-for-targeted-cancer-treatment 2025-05-06T05:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/renovorx-secures-new-u-s-patent-for-tamp-therapy-platform-strengthening-ip-portfolio-for-targeted-cancer-treatment 2025-05-06T05:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-ide-for-ecm-therapeutics-novel-hydrogel-treatment-for-anorectal-fistulas 2025-05-06T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-ide-for-ecm-therapeutics-novel-hydrogel-treatment-for-anorectal-fistulas 2025-05-06T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ge-healthcare-s-aurora-spect-ct-and-clarify-dl-receive-fda-clearance-advancing-nuclear-medicine-imaging 2025-05-06T04:40:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ge-healthcare-s-aurora-spect-ct-and-clarify-dl-receive-fda-clearance-advancing-nuclear-medicine-imaging 2025-05-06T04:40:27+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-ritedose-s-albuterol-sulfate-inhalation-solution-amid-national-shortage 2025-05-06T04:40:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-ritedose-s-albuterol-sulfate-inhalation-solution-amid-national-shortage 2025-05-06T04:40:26+00:00 hourly 0.9 https://trial.medpath.com/news/fangzhou-expands-access-to-breakthrough-leukemia-treatment-with-ponatinib-launch-in-china 2025-05-06T04:40:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fangzhou-expands-access-to-breakthrough-leukemia-treatment-with-ponatinib-launch-in-china 2025-05-06T04:40:20+00:00 hourly 0.9 https://trial.medpath.com/news/beijing-tide-s-first-in-class-at2r-antagonist-trd205-enters-phase-ii-trials-for-chronic-post-surgical-pain 2025-05-06T04:39:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beijing-tide-s-first-in-class-at2r-antagonist-trd205-enters-phase-ii-trials-for-chronic-post-surgical-pain 2025-05-06T04:39:48+00:00 hourly 0.9 https://trial.medpath.com/news/who-approves-naxtarubicin-as-international-generic-name-for-moleculin-s-cancer-drug-annamycin 2025-05-06T04:39:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/who-approves-naxtarubicin-as-international-generic-name-for-moleculin-s-cancer-drug-annamycin 2025-05-06T04:39:36+00:00 hourly 0.9 https://trial.medpath.com/news/ptc518-shows-promise-in-huntington-s-disease-phase-2-trial-meets-primary-endpoint 2025-05-06T04:38:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ptc518-shows-promise-in-huntington-s-disease-phase-2-trial-meets-primary-endpoint 2025-05-06T04:38:42+00:00 hourly 0.9 https://trial.medpath.com/news/trump-administration-s-clinical-trial-system-shutdown-shocks-medical-research-community 2025-05-06T04:38:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trump-administration-s-clinical-trial-system-shutdown-shocks-medical-research-community 2025-05-06T04:38:41+00:00 hourly 0.9 https://trial.medpath.com/news/daridorexant-shows-promising-results-in-improving-night-to-day-transition-for-insomnia-patients 2025-05-06T04:38:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/daridorexant-shows-promising-results-in-improving-night-to-day-transition-for-insomnia-patients 2025-05-06T04:38:36+00:00 hourly 0.9 https://trial.medpath.com/news/innovent-s-efdamrofusp-alfa-shows-promising-results-for-neovascular-amd-with-extended-dosing-potential 2025-05-06T04:38:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/innovent-s-efdamrofusp-alfa-shows-promising-results-for-neovascular-amd-with-extended-dosing-potential 2025-05-06T04:38:31+00:00 hourly 0.9 https://trial.medpath.com/news/jnj-1900-shows-promise-in-phase-1-trial-for-advanced-pancreatic-cancer 2025-05-06T04:38:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jnj-1900-shows-promise-in-phase-1-trial-for-advanced-pancreatic-cancer 2025-05-06T04:38:27+00:00 hourly 0.9 https://trial.medpath.com/news/scribe-therapeutics-to-present-novel-crispr-based-gene-therapy-data-for-duchenne-muscular-dystrophy-at-asgct-2025 2025-05-06T04:36:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scribe-therapeutics-to-present-novel-crispr-based-gene-therapy-data-for-duchenne-muscular-dystrophy-at-asgct-2025 2025-05-06T04:36:43+00:00 hourly 0.9 https://trial.medpath.com/news/theralase-s-light-activated-ruvidar-shows-promising-results-in-bcg-unresponsive-bladder-cancer-clinical-trial 2025-05-06T04:36:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/theralase-s-light-activated-ruvidar-shows-promising-results-in-bcg-unresponsive-bladder-cancer-clinical-trial 2025-05-06T04:36:06+00:00 hourly 0.9 https://trial.medpath.com/news/car-t-cell-therapies-drive-growth-in-adult-t-cell-leukemia-lymphoma-market-despite-access-challenges 2025-05-06T04:32:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/car-t-cell-therapies-drive-growth-in-adult-t-cell-leukemia-lymphoma-market-despite-access-challenges 2025-05-06T04:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/integra-therapeutics-and-factor-bioscience-showcase-advanced-gene-editing-technologies-for-car-t-cell-therapies-at-asgct-2025 2025-05-06T04:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/integra-therapeutics-and-factor-bioscience-showcase-advanced-gene-editing-technologies-for-car-t-cell-therapies-at-asgct-2025 2025-05-06T04:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/genprex-secures-exclusive-license-for-reqorsa-gene-therapy-in-glioblastoma-treatment 2025-05-06T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genprex-secures-exclusive-license-for-reqorsa-gene-therapy-in-glioblastoma-treatment 2025-05-06T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/lundbeck-partners-with-dcai-to-accelerate-brain-disorder-drug-discovery-using-gefion-ai-supercomputer 2025-05-06T02:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lundbeck-partners-with-dcai-to-accelerate-brain-disorder-drug-discovery-using-gefion-ai-supercomputer 2025-05-06T02:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/inbrain-neuroelectronics-secures-eur4-million-grant-to-advance-graphene-based-brain-computer-interface-technology 2025-05-06T02:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inbrain-neuroelectronics-secures-eur4-million-grant-to-advance-graphene-based-brain-computer-interface-technology 2025-05-06T02:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/repose-study-confirms-real-world-efficacy-of-higher-dose-onabotulinumtoxina-for-chronic-migraine 2025-05-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/repose-study-confirms-real-world-efficacy-of-higher-dose-onabotulinumtoxina-for-chronic-migraine 2025-05-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ousia-pharma-secures-seed-financing-from-omega-funds-to-develop-novel-obesity-treatment-targeting-nmda-receptors 2025-05-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ousia-pharma-secures-seed-financing-from-omega-funds-to-develop-novel-obesity-treatment-targeting-nmda-receptors 2025-05-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/dynamic-biomarkers-show-promise-for-predicting-immune-checkpoint-inhibitor-response-in-cancer-patients 2025-05-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dynamic-biomarkers-show-promise-for-predicting-immune-checkpoint-inhibitor-response-in-cancer-patients 2025-05-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/agendia-s-blueprint-test-shows-promise-in-identifying-chemotherapy-responsive-breast-cancer-subtypes 2025-05-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/agendia-s-blueprint-test-shows-promise-in-identifying-chemotherapy-responsive-breast-cancer-subtypes 2025-05-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/lilly-partners-with-creyon-bio-in-1b-deal-to-develop-ai-designed-rna-therapies 2025-05-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lilly-partners-with-creyon-bio-in-1b-deal-to-develop-ai-designed-rna-therapies 2025-05-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/sk-bioscience-selected-for-korea-s-national-avian-influenza-vaccine-development-program 2025-05-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sk-bioscience-selected-for-korea-s-national-avian-influenza-vaccine-development-program 2025-05-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cbd-life-sciences-expands-global-footprint-with-strategic-manufacturing-partnerships-in-colombia-and-u-s 2025-05-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cbd-life-sciences-expands-global-footprint-with-strategic-manufacturing-partnerships-in-colombia-and-u-s 2025-05-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/endospan-s-nexus-aortic-arch-stent-graft-shows-promising-30-day-results-in-fda-triomphe-trial 2025-05-05T20:27:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/endospan-s-nexus-aortic-arch-stent-graft-shows-promising-30-day-results-in-fda-triomphe-trial 2025-05-05T20:27:00+00:00 hourly 0.9 https://trial.medpath.com/news/kane-biotech-secures-2-2-million-through-private-placement-and-insider-loan-to-advance-biofilm-disrupting-wound-care-technology 2025-05-05T17:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kane-biotech-secures-2-2-million-through-private-placement-and-insider-loan-to-advance-biofilm-disrupting-wound-care-technology 2025-05-05T17:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/new-jersey-transforms-cancer-care-landscape-with-first-freestanding-cancer-hospital 2025-05-05T15:39:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-jersey-transforms-cancer-care-landscape-with-first-freestanding-cancer-hospital 2025-05-05T15:39:00+00:00 hourly 0.9 https://trial.medpath.com/news/ferring-s-iris-study-demonstrates-improved-ivf-outcomes-with-individualized-follitropin-delta-dosing-in-indian-patients 2025-05-05T15:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ferring-s-iris-study-demonstrates-improved-ivf-outcomes-with-individualized-follitropin-delta-dosing-in-indian-patients 2025-05-05T15:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cannabix-technologies-secures-nhtsa-approval-and-manufacturing-partnership-for-breathlogix-alcohol-screening-device 2025-05-05T14:45:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cannabix-technologies-secures-nhtsa-approval-and-manufacturing-partnership-for-breathlogix-alcohol-screening-device 2025-05-05T14:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/pharmacy-industry-fellowships-a-critical-pathway-for-pharmd-graduates-career-development 2025-05-05T14:14:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharmacy-industry-fellowships-a-critical-pathway-for-pharmd-graduates-career-development 2025-05-05T14:14:35+00:00 hourly 0.9 https://trial.medpath.com/news/ascendis-pharma-presents-long-term-data-on-rare-endocrine-disease-therapies-at-major-medical-conferences 2025-05-05T12:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ascendis-pharma-presents-long-term-data-on-rare-endocrine-disease-therapies-at-major-medical-conferences 2025-05-05T12:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/regeneration-biomedical-reports-promising-phase-1-results-for-direct-brain-injection-of-stem-cells-in-alzheimer-s-disease 2025-05-05T12:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regeneration-biomedical-reports-promising-phase-1-results-for-direct-brain-injection-of-stem-cells-in-alzheimer-s-disease 2025-05-05T12:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/texas-girl-to-make-medical-history-with-first-ever-treatment-for-rare-nars1-genetic-disorder 2025-05-05T11:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/texas-girl-to-make-medical-history-with-first-ever-treatment-for-rare-nars1-genetic-disorder 2025-05-05T11:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/new-phase-1-trial-combines-tagraxofusp-and-pacritinib-for-treatment-resistant-myelofibrosis 2025-05-05T09:36:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-phase-1-trial-combines-tagraxofusp-and-pacritinib-for-treatment-resistant-myelofibrosis 2025-05-05T09:36:38+00:00 hourly 0.9 https://trial.medpath.com/news/autonomix-medical-reports-significant-pain-reduction-in-pancreatic-cancer-patients-with-novel-nerve-ablation-technique 2025-05-05T08:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/autonomix-medical-reports-significant-pain-reduction-in-pancreatic-cancer-patients-with-novel-nerve-ablation-technique 2025-05-05T08:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/ontada-presents-14-real-world-evidence-studies-at-ispor-2025-to-advance-cancer-care-research 2025-05-05T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ontada-presents-14-real-world-evidence-studies-at-ispor-2025-to-advance-cancer-care-research 2025-05-05T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/dual-target-alzheimer-s-vaccine-duvax-receives-3-million-nih-grant-for-phase-1-trials 2025-05-05T07:56:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dual-target-alzheimer-s-vaccine-duvax-receives-3-million-nih-grant-for-phase-1-trials 2025-05-05T07:56:00+00:00 hourly 0.9 https://trial.medpath.com/news/palatin-s-pl9588-shows-promise-as-dual-action-glaucoma-therapy-with-neuroprotective-effects 2025-05-05T07:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/palatin-s-pl9588-shows-promise-as-dual-action-glaucoma-therapy-with-neuroprotective-effects 2025-05-05T07:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/janux-therapeutics-advances-janx007-to-phase-1b-trials-for-prostate-cancer-with-promising-survival-data 2025-05-05T05:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/janux-therapeutics-advances-janx007-to-phase-1b-trials-for-prostate-cancer-with-promising-survival-data 2025-05-05T05:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/targeted-therapies-transform-biliary-tract-cancer-treatment-as-her2-directed-agents-gain-fda-approval 2025-05-05T05:15:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/targeted-therapies-transform-biliary-tract-cancer-treatment-as-her2-directed-agents-gain-fda-approval 2025-05-05T05:15:51+00:00 hourly 0.9 https://trial.medpath.com/news/brain-cancer-canada-awards-170k-for-two-glioblastoma-research-projects-targeting-treatment-resistance 2025-05-05T05:09:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brain-cancer-canada-awards-170k-for-two-glioblastoma-research-projects-targeting-treatment-resistance 2025-05-05T05:09:00+00:00 hourly 0.9 https://trial.medpath.com/news/bionxt-solutions-secures-eurasian-patent-approval-for-sublingual-ms-treatment-technology 2025-05-05T03:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bionxt-solutions-secures-eurasian-patent-approval-for-sublingual-ms-treatment-technology 2025-05-05T03:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/biomed-industries-reports-phase-2-success-for-oral-obesity-drug-na-931-at-ada-2025 2025-05-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biomed-industries-reports-phase-2-success-for-oral-obesity-drug-na-931-at-ada-2025 2025-05-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/crispr-gene-editing-therapy-shows-promise-in-first-human-trial-for-advanced-gi-cancers 2025-05-04T16:34:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crispr-gene-editing-therapy-shows-promise-in-first-human-trial-for-advanced-gi-cancers 2025-05-04T16:34:01+00:00 hourly 0.9 https://trial.medpath.com/news/fda-to-slash-drug-approval-times-by-half-with-new-streamlined-procedures 2025-05-04T16:33:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-to-slash-drug-approval-times-by-half-with-new-streamlined-procedures 2025-05-04T16:33:54+00:00 hourly 0.9 https://trial.medpath.com/news/fda-expands-quikclot-control-hemostatic-device-indications-to-all-bleeding-grades 2025-05-04T16:33:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-expands-quikclot-control-hemostatic-device-indications-to-all-bleeding-grades 2025-05-04T16:33:52+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-ind-for-nutshell-therapeutics-novel-p53-y220c-reactivator-nts071 2025-05-04T13:34:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-ind-for-nutshell-therapeutics-novel-p53-y220c-reactivator-nts071 2025-05-04T13:34:06+00:00 hourly 0.9 https://trial.medpath.com/news/home-administration-of-long-acting-hiv-injectable-therapy-proves-safe-and-effective-as-clinic-treatment 2025-05-04T04:34:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/home-administration-of-long-acting-hiv-injectable-therapy-proves-safe-and-effective-as-clinic-treatment 2025-05-04T04:34:52+00:00 hourly 0.9 https://trial.medpath.com/news/io-biotech-s-novel-immune-modulatory-cancer-vaccine-shows-promise-in-phase-3-trials 2025-05-04T04:34:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/io-biotech-s-novel-immune-modulatory-cancer-vaccine-shows-promise-in-phase-3-trials 2025-05-04T04:34:45+00:00 hourly 0.9 https://trial.medpath.com/news/combination-therapy-shows-promise-for-hepatitis-b-functional-cure-with-100-sustained-seroconversion-in-preclinical-study 2025-05-04T01:35:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/combination-therapy-shows-promise-for-hepatitis-b-functional-cure-with-100-sustained-seroconversion-in-preclinical-study 2025-05-04T01:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/district-court-dismisses-united-therapeutics-dispute-against-liquidia-in-patent-litigation 2025-05-03T20:05:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/district-court-dismisses-united-therapeutics-dispute-against-liquidia-in-patent-litigation 2025-05-03T20:05:58+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-hyderabad-and-krismo-biosciences-partner-to-develop-novel-therapies-for-inflammatory-diseases-and-viral-infections 2025-05-03T19:34:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/university-of-hyderabad-and-krismo-biosciences-partner-to-develop-novel-therapies-for-inflammatory-diseases-and-viral-infections 2025-05-03T19:34:04+00:00 hourly 0.9 https://trial.medpath.com/news/tae-life-sciences-and-ohio-state-university-partner-to-advance-boron-neutron-capture-therapy-for-cancer-treatment 2025-05-03T16:35:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tae-life-sciences-and-ohio-state-university-partner-to-advance-boron-neutron-capture-therapy-for-cancer-treatment 2025-05-03T16:35:37+00:00 hourly 0.9 https://trial.medpath.com/news/complicated-urinary-tract-infection-pipeline-shows-robust-development-with-12-companies-advancing-novel-therapies 2025-05-03T16:35:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/complicated-urinary-tract-infection-pipeline-shows-robust-development-with-12-companies-advancing-novel-therapies 2025-05-03T16:35:30+00:00 hourly 0.9 https://trial.medpath.com/news/risankizumab-and-guselkumab-show-comparable-efficacy-in-real-world-psoriasis-treatment-over-one-year 2025-05-03T16:34:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/risankizumab-and-guselkumab-show-comparable-efficacy-in-real-world-psoriasis-treatment-over-one-year 2025-05-03T16:34:59+00:00 hourly 0.9 https://trial.medpath.com/news/summit-therapeutics-ivonescimab-shows-promising-results-in-phase-3-nsclc-trial 2025-05-03T13:35:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/summit-therapeutics-ivonescimab-shows-promising-results-in-phase-3-nsclc-trial 2025-05-03T13:35:10+00:00 hourly 0.9 https://trial.medpath.com/news/tissuecypher-test-shows-promise-in-identifying-barrett-s-esophagus-patients-at-risk-for-esophageal-cancer 2025-05-03T13:35:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tissuecypher-test-shows-promise-in-identifying-barrett-s-esophagus-patients-at-risk-for-esophageal-cancer 2025-05-03T13:35:05+00:00 hourly 0.9 https://trial.medpath.com/news/pliant-therapeutics-cuts-workforce-by-45-following-termination-of-idiopathic-pulmonary-fibrosis-trial 2025-05-03T13:35:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pliant-therapeutics-cuts-workforce-by-45-following-termination-of-idiopathic-pulmonary-fibrosis-trial 2025-05-03T13:35:01+00:00 hourly 0.9 https://trial.medpath.com/news/novel-smart-capsule-technology-could-revolutionize-multi-medication-regimens 2025-05-03T11:34:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-smart-capsule-technology-could-revolutionize-multi-medication-regimens 2025-05-03T11:34:42+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approved-pinworm-drug-shows-promise-against-deadly-merkel-cell-carcinoma 2025-05-03T10:35:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approved-pinworm-drug-shows-promise-against-deadly-merkel-cell-carcinoma 2025-05-03T10:35:02+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-universal-antivenom-developed-using-blood-of-man-bitten-200-times 2025-05-03T10:35:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-universal-antivenom-developed-using-blood-of-man-bitten-200-times 2025-05-03T10:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/zucara-therapeutics-secures-25m-series-b-funding-to-advance-first-in-class-hypoglycemia-prevention-therapy 2025-05-03T07:36:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zucara-therapeutics-secures-25m-series-b-funding-to-advance-first-in-class-hypoglycemia-prevention-therapy 2025-05-03T07:36:03+00:00 hourly 0.9 https://trial.medpath.com/news/faricimab-shows-superior-fluid-reduction-and-sustained-efficacy-in-wet-amd-through-3-year-data 2025-05-03T07:35:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/faricimab-shows-superior-fluid-reduction-and-sustained-efficacy-in-wet-amd-through-3-year-data 2025-05-03T07:35:16+00:00 hourly 0.9 https://trial.medpath.com/news/evolving-treatment-landscape-for-egfr-mutant-nsclc-managing-resistance-and-optimizing-therapy-sequence 2025-05-03T04:39:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evolving-treatment-landscape-for-egfr-mutant-nsclc-managing-resistance-and-optimizing-therapy-sequence 2025-05-03T04:39:47+00:00 hourly 0.9 https://trial.medpath.com/news/immuneoncia-therapeutics-raises-24m-in-successful-kosdaq-ipo-for-cancer-drug-development 2025-05-03T01:35:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immuneoncia-therapeutics-raises-24m-in-successful-kosdaq-ipo-for-cancer-drug-development 2025-05-03T01:35:57+00:00 hourly 0.9 https://trial.medpath.com/news/court-dismisses-united-therapeutics-challenge-against-liquidia-s-yutrepia-clearing-path-for-may-launch 2025-05-03T01:35:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/court-dismisses-united-therapeutics-challenge-against-liquidia-s-yutrepia-clearing-path-for-may-launch 2025-05-03T01:35:16+00:00 hourly 0.9 https://trial.medpath.com/news/edwards-lifesciences-receives-fda-approval-for-tavr-therapy-in-asymptomatic-severe-aortic-stenosis 2025-05-02T22:35:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/edwards-lifesciences-receives-fda-approval-for-tavr-therapy-in-asymptomatic-severe-aortic-stenosis 2025-05-02T22:35:15+00:00 hourly 0.9 https://trial.medpath.com/news/abbott-partners-with-epic-to-integrate-freestyle-libre-cgm-data-into-electronic-health-records 2025-05-02T20:04:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbott-partners-with-epic-to-integrate-freestyle-libre-cgm-data-into-electronic-health-records 2025-05-02T20:04:13+00:00 hourly 0.9 https://trial.medpath.com/news/thermo-fisher-scientific-partners-with-roosterbio-to-accelerate-cell-and-exosome-therapy-development 2025-05-02T20:04:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/thermo-fisher-scientific-partners-with-roosterbio-to-accelerate-cell-and-exosome-therapy-development 2025-05-02T20:04:11+00:00 hourly 0.9 https://trial.medpath.com/news/genmab-plans-fda-submission-for-epcoritamab-combination-therapy-in-relapsed-follicular-lymphoma 2025-05-02T19:35:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genmab-plans-fda-submission-for-epcoritamab-combination-therapy-in-relapsed-follicular-lymphoma 2025-05-02T19:35:20+00:00 hourly 0.9 https://trial.medpath.com/news/turn-therapeutics-achieves-breakthrough-in-room-temperature-vaccine-stability 2025-05-02T19:35:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/turn-therapeutics-achieves-breakthrough-in-room-temperature-vaccine-stability 2025-05-02T19:35:15+00:00 hourly 0.9 https://trial.medpath.com/news/study-confirms-clinical-trial-results-accurately-predict-real-world-benefits-of-prostate-cancer-therapies 2025-05-02T19:34:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-confirms-clinical-trial-results-accurately-predict-real-world-benefits-of-prostate-cancer-therapies 2025-05-02T19:34:25+00:00 hourly 0.9 https://trial.medpath.com/news/amgen-s-stelara-biosimilar-generates-150-million-in-first-quarter-highlighting-biosimilar-strategy-success 2025-05-02T16:38:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amgen-s-stelara-biosimilar-generates-150-million-in-first-quarter-highlighting-biosimilar-strategy-success 2025-05-02T16:38:09+00:00 hourly 0.9 https://trial.medpath.com/news/sohm-recruits-car-t-expert-dr-leonardo-mirandola-to-advance-novel-gene-editing-platform-toward-clinical-trials 2025-05-02T16:37:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sohm-recruits-car-t-expert-dr-leonardo-mirandola-to-advance-novel-gene-editing-platform-toward-clinical-trials 2025-05-02T16:37:32+00:00 hourly 0.9 https://trial.medpath.com/news/alembic-pharmaceuticals-receives-fda-approval-for-generic-ticagrelor-tablets-to-reduce-cardiovascular-risks 2025-05-02T16:37:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alembic-pharmaceuticals-receives-fda-approval-for-generic-ticagrelor-tablets-to-reduce-cardiovascular-risks 2025-05-02T16:37:04+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-drug-trial-shows-life-changing-results-for-children-with-dravet-syndrome 2025-05-02T16:35:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-drug-trial-shows-life-changing-results-for-children-with-dravet-syndrome 2025-05-02T16:35:58+00:00 hourly 0.9 https://trial.medpath.com/news/novel-in-vivo-cd19-car-t-therapy-achieves-complete-remission-in-aggressive-dlbcl-without-lymphodepletion 2025-05-02T15:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-in-vivo-cd19-car-t-therapy-achieves-complete-remission-in-aggressive-dlbcl-without-lymphodepletion 2025-05-02T15:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-to-present-groundbreaking-respiratory-medicine-data-at-ats-2025-international-congress 2025-05-02T13:40:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-to-present-groundbreaking-respiratory-medicine-data-at-ats-2025-international-congress 2025-05-02T13:40:44+00:00 hourly 0.9 https://trial.medpath.com/news/fda-denies-cytosorbents-de-novo-request-for-drugsorb-atr-blood-purification-device 2025-05-02T13:40:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-denies-cytosorbents-de-novo-request-for-drugsorb-atr-blood-purification-device 2025-05-02T13:40:42+00:00 hourly 0.9 https://trial.medpath.com/news/first-patient-dosed-in-phase-1-trial-of-kh658-gene-therapy-for-wet-amd 2025-05-02T13:39:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-patient-dosed-in-phase-1-trial-of-kh658-gene-therapy-for-wet-amd 2025-05-02T13:39:39+00:00 hourly 0.9 https://trial.medpath.com/news/cour-pharma-initiates-cnp-103-clinical-trial-for-newly-diagnosed-type-1-diabetes-patients 2025-05-02T13:27:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cour-pharma-initiates-cnp-103-clinical-trial-for-newly-diagnosed-type-1-diabetes-patients 2025-05-02T13:27:43+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-s-weight-loss-drug-wegovy-now-available-in-qatar-through-ebn-sina-medical-partnership 2025-05-02T11:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-nordisk-s-weight-loss-drug-wegovy-now-available-in-qatar-through-ebn-sina-medical-partnership 2025-05-02T11:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/nhs-explores-pharmacy-based-weight-loss-injection-program-to-expand-access-at-prescription-prices 2025-05-02T10:45:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nhs-explores-pharmacy-based-weight-loss-injection-program-to-expand-access-at-prescription-prices 2025-05-02T10:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/anavex-completes-enrollment-in-phase-2-trial-of-anavex-r-3-71-for-schizophrenia-treatment 2025-05-02T10:36:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/anavex-completes-enrollment-in-phase-2-trial-of-anavex-r-3-71-for-schizophrenia-treatment 2025-05-02T10:36:06+00:00 hourly 0.9 https://trial.medpath.com/news/shashvi-remedies-secures-rs-10-lakh-grant-for-breakthrough-breast-cancer-treatment-patent 2025-05-02T10:35:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shashvi-remedies-secures-rs-10-lakh-grant-for-breakthrough-breast-cancer-treatment-patent 2025-05-02T10:35:56+00:00 hourly 0.9 https://trial.medpath.com/news/iq-ai-seeks-fda-breakthrough-therapy-designation-for-promising-glioblastoma-treatment 2025-05-02T10:35:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iq-ai-seeks-fda-breakthrough-therapy-designation-for-promising-glioblastoma-treatment 2025-05-02T10:35:54+00:00 hourly 0.9 https://trial.medpath.com/news/metformin-shows-promise-in-reducing-knee-osteoarthritis-pain-in-overweight-patients 2025-05-02T10:05:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/metformin-shows-promise-in-reducing-knee-osteoarthritis-pain-in-overweight-patients 2025-05-02T10:05:35+00:00 hourly 0.9 https://trial.medpath.com/news/global-study-reveals-significant-gender-disparities-in-health-outcomes 2025-05-02T10:05:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-study-reveals-significant-gender-disparities-in-health-outcomes 2025-05-02T10:05:04+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-s-breztri-shows-significant-improvement-in-phase-iii-asthma-trials 2025-05-02T07:35:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-s-breztri-shows-significant-improvement-in-phase-iii-asthma-trials 2025-05-02T07:35:26+00:00 hourly 0.9 https://trial.medpath.com/news/amgen-reports-strong-global-demand-in-q1-2025-bolstering-long-term-growth-outlook 2025-05-02T07:35:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amgen-reports-strong-global-demand-in-q1-2025-bolstering-long-term-growth-outlook 2025-05-02T07:35:24+00:00 hourly 0.9 https://trial.medpath.com/news/biogen-advances-leqembi-treatment-with-subcutaneous-formulation-for-alzheimer-s-disease 2025-05-02T07:05:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biogen-advances-leqembi-treatment-with-subcutaneous-formulation-for-alzheimer-s-disease 2025-05-02T07:05:44+00:00 hourly 0.9 https://trial.medpath.com/news/endoform-natural-demonstrates-significant-healing-advantage-for-venous-leg-ulcers-in-large-real-world-study 2025-05-02T05:34:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/endoform-natural-demonstrates-significant-healing-advantage-for-venous-leg-ulcers-in-large-real-world-study 2025-05-02T05:34:57+00:00 hourly 0.9 https://trial.medpath.com/news/aventus-thrombectomy-system-shows-promise-for-pulmonary-embolism-treatment-in-pivotal-trial 2025-05-02T05:07:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aventus-thrombectomy-system-shows-promise-for-pulmonary-embolism-treatment-in-pivotal-trial 2025-05-02T05:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/histoindex-secures-9-million-investment-to-advance-ai-powered-liver-disease-diagnostics 2025-05-02T04:35:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/histoindex-secures-9-million-investment-to-advance-ai-powered-liver-disease-diagnostics 2025-05-02T04:35:21+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-data-emerges-as-key-solution-to-oncology-treatment-challenges 2025-05-02T04:35:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-data-emerges-as-key-solution-to-oncology-treatment-challenges 2025-05-02T04:35:19+00:00 hourly 0.9 https://trial.medpath.com/news/study-reveals-significant-pregnancy-risks-for-minority-women-with-cancer 2025-05-02T02:39:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-reveals-significant-pregnancy-risks-for-minority-women-with-cancer 2025-05-02T02:39:41+00:00 hourly 0.9 https://trial.medpath.com/news/vibegron-shows-sustained-long-term-safety-and-efficacy-for-men-with-oab-and-bph 2025-05-02T01:40:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vibegron-shows-sustained-long-term-safety-and-efficacy-for-men-with-oab-and-bph 2025-05-02T01:40:27+00:00 hourly 0.9 https://trial.medpath.com/news/novel-nucleus-pulposus-allograft-shows-promise-for-chronic-back-pain-treatment 2025-05-02T01:40:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-nucleus-pulposus-allograft-shows-promise-for-chronic-back-pain-treatment 2025-05-02T01:40:17+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-ocumet-beacon-a-novel-non-invasive-retinal-imaging-device 2025-05-02T01:39:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-ocumet-beacon-a-novel-non-invasive-retinal-imaging-device 2025-05-02T01:39:35+00:00 hourly 0.9 https://trial.medpath.com/news/repare-therapeutics-licenses-discovery-platforms-to-dcx-biotherapeutics-in-strategic-refocus-on-clinical-pipeline 2025-05-02T01:39:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/repare-therapeutics-licenses-discovery-platforms-to-dcx-biotherapeutics-in-strategic-refocus-on-clinical-pipeline 2025-05-02T01:39:25+00:00 hourly 0.9 https://trial.medpath.com/news/foresee-pharmaceuticals-launches-phase-2-trial-of-mirivadelgat-for-pulmonary-hypertension-associated-with-interstitial-lung-disease 2025-05-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/foresee-pharmaceuticals-launches-phase-2-trial-of-mirivadelgat-for-pulmonary-hypertension-associated-with-interstitial-lung-disease 2025-05-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bluenalu-expands-partnership-with-nomadfoods-to-commercialise-cell-based-products-in-uk-europe 2025-05-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bluenalu-expands-partnership-with-nomadfoods-to-commercialise-cell-based-products-in-uk-europe 2025-05-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/gene-therapy-shows-promising-results-in-children-with-rare-immune-disorder-lad-i 2025-05-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gene-therapy-shows-promising-results-in-children-with-rare-immune-disorder-lad-i 2025-05-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/alk-and-ars-pharma-partner-to-co-promote-neffy-first-needle-free-epinephrine-nasal-spray-for-anaphylaxis 2025-05-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alk-and-ars-pharma-partner-to-co-promote-neffy-first-needle-free-epinephrine-nasal-spray-for-anaphylaxis 2025-05-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-advances-azd0780-cholesterol-lowering-drug-through-phase-ii-and-iii-clinical-trials 2025-05-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-advances-azd0780-cholesterol-lowering-drug-through-phase-ii-and-iii-clinical-trials 2025-05-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-s-combination-mrna-vaccine-for-covid-19-and-influenza-shows-promise-in-phase-3-trial 2025-05-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moderna-s-combination-mrna-vaccine-for-covid-19-and-influenza-shows-promise-in-phase-3-trial 2025-05-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/single-antiplatelet-therapy-shows-superior-safety-profile-over-dual-therapy-after-tavr 2025-05-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/single-antiplatelet-therapy-shows-superior-safety-profile-over-dual-therapy-after-tavr 2025-05-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/dupilumab-shows-sustained-lung-function-improvements-in-copd-patients-with-type-2-inflammation 2025-05-01T23:00:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dupilumab-shows-sustained-lung-function-improvements-in-copd-patients-with-type-2-inflammation 2025-05-01T23:00:48+00:00 hourly 0.9 https://trial.medpath.com/news/strides-pharma-secures-usfda-approval-for-celecoxib-capsules-targeting-116m-market 2025-05-01T22:36:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/strides-pharma-secures-usfda-approval-for-celecoxib-capsules-targeting-116m-market 2025-05-01T22:36:38+00:00 hourly 0.9 https://trial.medpath.com/news/new-bone-marrow-test-could-double-survival-rates-for-acute-myeloid-leukemia-patients 2025-05-01T20:33:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-bone-marrow-test-could-double-survival-rates-for-acute-myeloid-leukemia-patients 2025-05-01T20:33:57+00:00 hourly 0.9 https://trial.medpath.com/news/cnd-life-sciences-secures-13-5m-series-a-funding-to-advance-skin-based-neurodegenerative-disease-diagnostics 2025-05-01T20:04:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cnd-life-sciences-secures-13-5m-series-a-funding-to-advance-skin-based-neurodegenerative-disease-diagnostics 2025-05-01T20:04:29+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-advances-liver-cancer-treatment-with-first-in-human-trial-of-novel-targeted-alpha-therapy 2025-05-01T20:03:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bayer-advances-liver-cancer-treatment-with-first-in-human-trial-of-novel-targeted-alpha-therapy 2025-05-01T20:03:52+00:00 hourly 0.9 https://trial.medpath.com/news/magnetic-silk-microparticles-a-breakthrough-for-targeted-drug-delivery 2025-05-01T19:36:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/magnetic-silk-microparticles-a-breakthrough-for-targeted-drug-delivery 2025-05-01T19:36:26+00:00 hourly 0.9 https://trial.medpath.com/news/fda-considers-new-conditional-approval-pathway-for-rare-disease-treatments 2025-05-01T19:36:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-considers-new-conditional-approval-pathway-for-rare-disease-treatments 2025-05-01T19:36:12+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-element-science-s-jewel-patch-a-revolutionary-wearable-defibrillator-for-sudden-cardiac-arrest-risk 2025-05-01T19:36:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-element-science-s-jewel-patch-a-revolutionary-wearable-defibrillator-for-sudden-cardiac-arrest-risk 2025-05-01T19:36:11+00:00 hourly 0.9 https://trial.medpath.com/news/hhs-and-nih-launch-generation-gold-standard-universal-vaccine-platform-to-combat-pandemic-threats 2025-05-01T19:34:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hhs-and-nih-launch-generation-gold-standard-universal-vaccine-platform-to-combat-pandemic-threats 2025-05-01T19:34:57+00:00 hourly 0.9 https://trial.medpath.com/news/who-set-to-endorse-glp-1-weight-loss-drugs-globally-addressing-access-challenges 2025-05-01T16:41:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/who-set-to-endorse-glp-1-weight-loss-drugs-globally-addressing-access-challenges 2025-05-01T16:41:21+00:00 hourly 0.9 https://trial.medpath.com/news/illumina-and-ovation-io-launch-groundbreaking-glp-1-dataset-to-transform-metabolic-disease-treatment 2025-05-01T16:40:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/illumina-and-ovation-io-launch-groundbreaking-glp-1-dataset-to-transform-metabolic-disease-treatment 2025-05-01T16:40:27+00:00 hourly 0.9 https://trial.medpath.com/news/biotech-dimerix-lands-940m-licensing-deal-for-kidney-drug-sales-afr 2025-05-01T16:39:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biotech-dimerix-lands-940m-licensing-deal-for-kidney-drug-sales-afr 2025-05-01T16:39:03+00:00 hourly 0.9 https://trial.medpath.com/news/qps-india-successfully-completes-us-fda-regulatory-inspection-marking-46th-regulatory-approval 2025-05-01T16:38:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/qps-india-successfully-completes-us-fda-regulatory-inspection-marking-46th-regulatory-approval 2025-05-01T16:38:44+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-tavr-therapy-for-asymptomatic-severe-aortic-stenosis-patients 2025-05-01T16:38:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-tavr-therapy-for-asymptomatic-severe-aortic-stenosis-patients 2025-05-01T16:38:42+00:00 hourly 0.9 https://trial.medpath.com/news/novel-bispecific-antibody-tarlatamab-shows-promise-in-relapsed-small-cell-lung-cancer 2025-05-01T16:37:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-bispecific-antibody-tarlatamab-shows-promise-in-relapsed-small-cell-lung-cancer 2025-05-01T16:37:46+00:00 hourly 0.9 https://trial.medpath.com/news/armata-s-bacteriophage-therapy-shows-promising-results-in-treating-staphylococcus-aureus-bacteremia 2025-05-01T16:36:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/armata-s-bacteriophage-therapy-shows-promising-results-in-treating-staphylococcus-aureus-bacteremia 2025-05-01T16:36:20+00:00 hourly 0.9 https://trial.medpath.com/news/us-biotech-companies-shift-clinical-trials-abroad-amid-fda-uncertainty 2025-05-01T16:36:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/us-biotech-companies-shift-clinical-trials-abroad-amid-fda-uncertainty 2025-05-01T16:36:13+00:00 hourly 0.9 https://trial.medpath.com/news/tempus-launches-time-precision-network-to-accelerate-phase-i-clinical-trial-enrollment 2025-05-01T16:35:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tempus-launches-time-precision-network-to-accelerate-phase-i-clinical-trial-enrollment 2025-05-01T16:35:31+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approved-cimerli-first-interchangeable-biosimilar-for-ocular-conditions-now-available 2025-05-01T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approved-cimerli-first-interchangeable-biosimilar-for-ocular-conditions-now-available 2025-05-01T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/amicus-therapeutics-reports-15-revenue-growth-in-q1-2025-expands-portfolio-with-dmx-200-licensing-deal 2025-05-01T14:03:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amicus-therapeutics-reports-15-revenue-growth-in-q1-2025-expands-portfolio-with-dmx-200-licensing-deal 2025-05-01T14:03:50+00:00 hourly 0.9 https://trial.medpath.com/news/aviadobio-completes-second-cohort-in-phase-1-2-trial-for-frontotemporal-dementia-gene-therapy 2025-05-01T13:59:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aviadobio-completes-second-cohort-in-phase-1-2-trial-for-frontotemporal-dementia-gene-therapy 2025-05-01T13:59:18+00:00 hourly 0.9 https://trial.medpath.com/news/biosplice-initiates-phase-2-trial-of-cirtuvivint-for-advanced-soft-tissue-sarcomas 2025-05-01T13:33:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biosplice-initiates-phase-2-trial-of-cirtuvivint-for-advanced-soft-tissue-sarcomas 2025-05-01T13:33:48+00:00 hourly 0.9 https://trial.medpath.com/news/ema-grants-positive-opinion-for-orphan-drug-designation-to-nuformix-s-nxp002-for-idiopathic-pulmonary-fibrosis 2025-05-01T10:33:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-grants-positive-opinion-for-orphan-drug-designation-to-nuformix-s-nxp002-for-idiopathic-pulmonary-fibrosis 2025-05-01T10:33:44+00:00 hourly 0.9 https://trial.medpath.com/news/bimekizumab-demonstrates-sustained-three-year-efficacy-in-psoriatic-arthritis-and-axial-spondyloarthritis 2025-05-01T09:54:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bimekizumab-demonstrates-sustained-three-year-efficacy-in-psoriatic-arthritis-and-axial-spondyloarthritis 2025-05-01T09:54:49+00:00 hourly 0.9 https://trial.medpath.com/news/statins-linked-to-61-reduced-cancer-mortality-in-cll-sll-patients-on-targeted-therapy 2025-05-01T09:12:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/statins-linked-to-61-reduced-cancer-mortality-in-cll-sll-patients-on-targeted-therapy 2025-05-01T09:12:00+00:00 hourly 0.9 https://trial.medpath.com/news/osstec-secures-ps2-5m-to-advance-3d-printed-joint-replacement-technology-to-us-market 2025-05-01T08:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/osstec-secures-ps2-5m-to-advance-3d-printed-joint-replacement-technology-to-us-market 2025-05-01T08:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/astellas-to-present-new-izervay-data-on-geographic-atrophy-at-major-ophthalmology-congresses 2025-05-01T08:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astellas-to-present-new-izervay-data-on-geographic-atrophy-at-major-ophthalmology-congresses 2025-05-01T08:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/adela-s-tissue-agnostic-mrd-test-shows-promise-for-predicting-immunotherapy-response-in-solid-tumors 2025-05-01T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adela-s-tissue-agnostic-mrd-test-shows-promise-for-predicting-immunotherapy-response-in-solid-tumors 2025-05-01T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/concentra-biosciences-acquires-two-biotech-companies-in-strategic-consolidation-move 2025-05-01T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/concentra-biosciences-acquires-two-biotech-companies-in-strategic-consolidation-move 2025-05-01T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/kennedy-mandates-placebo-testing-for-all-new-vaccines-potentially-impacting-fall-covid-boosters 2025-05-01T08:03:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kennedy-mandates-placebo-testing-for-all-new-vaccines-potentially-impacting-fall-covid-boosters 2025-05-01T08:03:39+00:00 hourly 0.9 https://trial.medpath.com/news/tirzepatide-shows-favorable-muscle-composition-changes-in-type-2-diabetes-patients-surpass-3-trial-analysis-reveals 2025-05-01T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tirzepatide-shows-favorable-muscle-composition-changes-in-type-2-diabetes-patients-surpass-3-trial-analysis-reveals 2025-05-01T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/common-cytomegalovirus-may-enhance-immunotherapy-outcomes-in-melanoma-patients-oxford-study-finds 2025-05-01T05:41:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/common-cytomegalovirus-may-enhance-immunotherapy-outcomes-in-melanoma-patients-oxford-study-finds 2025-05-01T05:41:02+00:00 hourly 0.9 https://trial.medpath.com/news/lexeo-therapeutics-to-showcase-advanced-aav-manufacturing-platform-at-asgct-annual-meeting 2025-05-01T05:12:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lexeo-therapeutics-to-showcase-advanced-aav-manufacturing-platform-at-asgct-annual-meeting 2025-05-01T05:12:00+00:00 hourly 0.9 https://trial.medpath.com/news/sapience-therapeutics-to-present-phase-2-lucicebtide-data-for-glioblastoma-at-asco-2025 2025-05-01T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sapience-therapeutics-to-present-phase-2-lucicebtide-data-for-glioblastoma-at-asco-2025 2025-05-01T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/haleon-partners-with-brightseed-to-leverage-ai-for-natural-bioactive-discovery-in-consumer-health 2025-05-01T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/haleon-partners-with-brightseed-to-leverage-ai-for-natural-bioactive-discovery-in-consumer-health 2025-05-01T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/stanford-health-care-deepens-integration-of-atropos-health-s-real-world-evidence-platform-into-clinical-workflow 2025-05-01T04:37:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stanford-health-care-deepens-integration-of-atropos-health-s-real-world-evidence-platform-into-clinical-workflow 2025-05-01T04:37:17+00:00 hourly 0.9 https://trial.medpath.com/news/supreme-court-demands-response-on-alleged-illegal-clinical-trials-at-gujarat-hospital 2025-05-01T04:37:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/supreme-court-demands-response-on-alleged-illegal-clinical-trials-at-gujarat-hospital 2025-05-01T04:37:09+00:00 hourly 0.9 https://trial.medpath.com/news/puretech-s-deupirfenidone-shows-unprecedented-efficacy-in-ipf-treatment-phase-2b-results-to-be-presented-at-ats-conference 2025-05-01T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/puretech-s-deupirfenidone-shows-unprecedented-efficacy-in-ipf-treatment-phase-2b-results-to-be-presented-at-ats-conference 2025-05-01T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-study-reveals-biomarker-status-drives-survival-and-cost-disparities-in-advanced-nsclc 2025-05-01T03:04:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-study-reveals-biomarker-status-drives-survival-and-cost-disparities-in-advanced-nsclc 2025-05-01T03:04:33+00:00 hourly 0.9 https://trial.medpath.com/news/study-reveals-long-term-organ-damage-in-children-following-covid-19-infection 2025-05-01T03:04:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-reveals-long-term-organ-damage-in-children-following-covid-19-infection 2025-05-01T03:04:32+00:00 hourly 0.9 https://trial.medpath.com/news/pl-bioscience-develops-world-s-first-artificial-human-platelet-lysate-for-cell-culture-applications 2025-05-01T03:04:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pl-bioscience-develops-world-s-first-artificial-human-platelet-lysate-for-cell-culture-applications 2025-05-01T03:04:28+00:00 hourly 0.9 https://trial.medpath.com/news/cancer-vaccines-emerge-as-promising-frontier-in-oncology-with-multiple-approaches-showing-clinical-success 2025-05-01T02:34:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cancer-vaccines-emerge-as-promising-frontier-in-oncology-with-multiple-approaches-showing-clinical-success 2025-05-01T02:34:05+00:00 hourly 0.9 https://trial.medpath.com/news/cml-treatment-market-poised-for-significant-growth-through-2032-amid-wave-of-recent-fda-approvals 2025-05-01T01:34:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cml-treatment-market-poised-for-significant-growth-through-2032-amid-wave-of-recent-fda-approvals 2025-05-01T01:34:29+00:00 hourly 0.9 https://trial.medpath.com/news/elite-pharmaceuticals-launches-generic-percocet-for-moderate-to-severe-pain-management 2025-05-01T01:34:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elite-pharmaceuticals-launches-generic-percocet-for-moderate-to-severe-pain-management 2025-05-01T01:34:24+00:00 hourly 0.9 https://trial.medpath.com/news/belfast-based-amply-discovery-secures-1-75m-to-accelerate-ai-driven-drug-development-for-cancer-and-antimicrobial-resistance 2025-05-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/belfast-based-amply-discovery-secures-1-75m-to-accelerate-ai-driven-drug-development-for-cancer-and-antimicrobial-resistance 2025-05-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-advances-baxdrostat-in-phase-iii-trials-for-uncontrolled-and-resistant-hypertension 2025-05-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-advances-baxdrostat-in-phase-iii-trials-for-uncontrolled-and-resistant-hypertension 2025-05-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/evotec-and-bristol-myers-squibb-achieve-major-milestone-in-molecular-glue-degrader-collaboration-triggering-75m-payment 2025-05-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evotec-and-bristol-myers-squibb-achieve-major-milestone-in-molecular-glue-degrader-collaboration-triggering-75m-payment 2025-05-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/akari-therapeutics-appoints-mark-f-kubik-to-lead-oncology-business-development-for-novel-adc-platform 2025-05-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/akari-therapeutics-appoints-mark-f-kubik-to-lead-oncology-business-development-for-novel-adc-platform 2025-05-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/enara-bio-strengthens-leadership-team-with-key-appointments-as-company-advances-dark-antigen-t-cell-engager-pipeline 2025-05-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enara-bio-strengthens-leadership-team-with-key-appointments-as-company-advances-dark-antigen-t-cell-engager-pipeline 2025-05-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-expands-virtual-clinical-trial-partnership-with-science-37-to-cut-r-d-costs 2025-05-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-expands-virtual-clinical-trial-partnership-with-science-37-to-cut-r-d-costs 2025-05-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-advances-two-novel-obesity-treatments-in-phase-iib-trials 2025-05-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-advances-two-novel-obesity-treatments-in-phase-iib-trials 2025-05-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-initiates-phase-i-studies-of-azd2389-for-liver-fibrosis-and-nash-treatment 2025-05-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-initiates-phase-i-studies-of-azd2389-for-liver-fibrosis-and-nash-treatment 2025-05-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/s-e-bio-secures-landmark-approval-for-first-exosome-based-stroke-therapy-trial-in-korea 2025-05-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/s-e-bio-secures-landmark-approval-for-first-exosome-based-stroke-therapy-trial-in-korea 2025-05-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/wegovy-shows-promise-in-treating-mash-a-serious-liver-disease 2025-04-30T23:04:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wegovy-shows-promise-in-treating-mash-a-serious-liver-disease 2025-04-30T23:04:51+00:00 hourly 0.9 https://trial.medpath.com/news/ema-approves-loba-biotech-as-new-manufacturing-site-for-pegasys-restoring-european-supply 2025-04-30T22:34:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-approves-loba-biotech-as-new-manufacturing-site-for-pegasys-restoring-european-supply 2025-04-30T22:34:06+00:00 hourly 0.9 https://trial.medpath.com/news/nccn-updates-breast-cancer-and-ovarian-cancer-treatment-guidelines-with-new-maintenance-therapy-and-immunotherapy-recommendations 2025-04-30T21:17:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nccn-updates-breast-cancer-and-ovarian-cancer-treatment-guidelines-with-new-maintenance-therapy-and-immunotherapy-recommendations 2025-04-30T21:17:12+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-s-zejula-shows-promising-results-in-phase-ii-mesothelioma-trial-with-27-reduction-in-disease-progression 2025-04-30T19:37:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-s-zejula-shows-promising-results-in-phase-ii-mesothelioma-trial-with-27-reduction-in-disease-progression 2025-04-30T19:37:35+00:00 hourly 0.9 https://trial.medpath.com/news/flagship-pioneering-appoints-biotech-veteran-rahul-kakkar-as-ceo-of-somatic-genomics-company-quotient-therapeutics 2025-04-30T19:37:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/flagship-pioneering-appoints-biotech-veteran-rahul-kakkar-as-ceo-of-somatic-genomics-company-quotient-therapeutics 2025-04-30T19:37:33+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-astrazeneca-s-imfinzi-for-perioperative-treatment-of-muscle-invasive-bladder-cancer 2025-04-30T17:37:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-astrazeneca-s-imfinzi-for-perioperative-treatment-of-muscle-invasive-bladder-cancer 2025-04-30T17:37:52+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-acquires-regulus-therapeutics-for-800m-expanding-kidney-disease-portfolio 2025-04-30T17:37:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-acquires-regulus-therapeutics-for-800m-expanding-kidney-disease-portfolio 2025-04-30T17:37:42+00:00 hourly 0.9 https://trial.medpath.com/news/geovax-advances-gedeptin-gene-therapy-for-solid-tumors-with-expanded-patent-portfolio-and-promising-clinical-data 2025-04-30T16:39:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/geovax-advances-gedeptin-gene-therapy-for-solid-tumors-with-expanded-patent-portfolio-and-promising-clinical-data 2025-04-30T16:39:33+00:00 hourly 0.9 https://trial.medpath.com/news/er-kim-and-puma-biotechnology-partner-to-bring-nerlynx-to-eastern-europe-and-central-asia-for-her2-positive-breast-cancer-patients 2025-04-30T16:38:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/er-kim-and-puma-biotechnology-partner-to-bring-nerlynx-to-eastern-europe-and-central-asia-for-her2-positive-breast-cancer-patients 2025-04-30T16:38:23+00:00 hourly 0.9 https://trial.medpath.com/news/predicta-biosciences-launches-genopredicta-a-novel-diagnostic-test-for-multiple-myeloma 2025-04-30T16:38:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/predicta-biosciences-launches-genopredicta-a-novel-diagnostic-test-for-multiple-myeloma 2025-04-30T16:38:14+00:00 hourly 0.9 https://trial.medpath.com/news/cytophage-launches-european-pilot-study-for-aviphage-targeting-antibiotic-free-poultry-production 2025-04-30T16:37:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cytophage-launches-european-pilot-study-for-aviphage-targeting-antibiotic-free-poultry-production 2025-04-30T16:37:36+00:00 hourly 0.9 https://trial.medpath.com/news/3p-innovation-launches-next-generation-dpi-filling-technology-promising-faster-production-of-inhalable-therapeutics 2025-04-30T16:37:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/3p-innovation-launches-next-generation-dpi-filling-technology-promising-faster-production-of-inhalable-therapeutics 2025-04-30T16:37:27+00:00 hourly 0.9 https://trial.medpath.com/news/miniject-shows-sustained-5-year-efficacy-in-glaucoma-treatment-istar-medical-reports 2025-04-30T16:34:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/miniject-shows-sustained-5-year-efficacy-in-glaucoma-treatment-istar-medical-reports 2025-04-30T16:34:21+00:00 hourly 0.9 https://trial.medpath.com/news/cessatech-s-ct001-nasal-spray-achieves-primary-endpoints-in-pivotal-pediatric-pain-study 2025-04-30T16:34:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cessatech-s-ct001-nasal-spray-achieves-primary-endpoints-in-pivotal-pediatric-pain-study 2025-04-30T16:34:19+00:00 hourly 0.9 https://trial.medpath.com/news/iterum-therapeutics-secures-5-million-in-funding-to-advance-commercialization-of-novel-antibiotic-orlynvah 2025-04-30T16:29:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iterum-therapeutics-secures-5-million-in-funding-to-advance-commercialization-of-novel-antibiotic-orlynvah 2025-04-30T16:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/histone-modifications-drive-tumor-associated-macrophage-polarization-in-cancer-immunotherapy 2025-04-30T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/histone-modifications-drive-tumor-associated-macrophage-polarization-in-cancer-immunotherapy 2025-04-30T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/metagenomic-next-generation-sequencing-demonstrates-superior-diagnostic-performance-for-severe-pneumonia-pathogen-detection 2025-04-30T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/metagenomic-next-generation-sequencing-demonstrates-superior-diagnostic-performance-for-severe-pneumonia-pathogen-detection 2025-04-30T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/alnylam-concedes-defeat-in-covid-19-vaccine-patent-dispute-with-pfizer-and-biontech 2025-04-30T15:48:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alnylam-concedes-defeat-in-covid-19-vaccine-patent-dispute-with-pfizer-and-biontech 2025-04-30T15:48:37+00:00 hourly 0.9 https://trial.medpath.com/news/pangia-biotech-to-present-ai-driven-urine-based-prostate-cancer-detection-platform-at-asco-2025 2025-04-30T15:16:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pangia-biotech-to-present-ai-driven-urine-based-prostate-cancer-detection-platform-at-asco-2025 2025-04-30T15:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/big-pharma-m-a-activity-surges-as-companies-target-undervalued-biotechs-amid-market-recovery 2025-04-30T14:55:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/big-pharma-m-a-activity-surges-as-companies-target-undervalued-biotechs-amid-market-recovery 2025-04-30T14:55:00+00:00 hourly 0.9 https://trial.medpath.com/news/alembic-pharma-shares-surge-following-usfda-clearance-of-panelav-oncology-facility 2025-04-30T14:52:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alembic-pharma-shares-surge-following-usfda-clearance-of-panelav-oncology-facility 2025-04-30T14:52:00+00:00 hourly 0.9 https://trial.medpath.com/news/jak-inhibitor-comparison-reveals-optimized-treatment-strategies-for-myelofibrosis-patients-with-cytopenias 2025-04-30T14:08:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jak-inhibitor-comparison-reveals-optimized-treatment-strategies-for-myelofibrosis-patients-with-cytopenias 2025-04-30T14:08:26+00:00 hourly 0.9 https://trial.medpath.com/news/zeiss-and-boehringer-ingelheim-partner-on-ai-powered-platform-to-transform-ophthalmic-research-and-personalized-eye-care 2025-04-30T13:41:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zeiss-and-boehringer-ingelheim-partner-on-ai-powered-platform-to-transform-ophthalmic-research-and-personalized-eye-care 2025-04-30T13:41:00+00:00 hourly 0.9 https://trial.medpath.com/news/neurocrine-biosciences-advances-novel-muscarinic-m4-agonist-to-phase-3-trials-for-schizophrenia 2025-04-30T13:35:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neurocrine-biosciences-advances-novel-muscarinic-m4-agonist-to-phase-3-trials-for-schizophrenia 2025-04-30T13:35:54+00:00 hourly 0.9 https://trial.medpath.com/news/hong-kong-approves-velsipity-r-for-moderately-to-severely-active-ulcerative-colitis 2025-04-30T13:35:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hong-kong-approves-velsipity-r-for-moderately-to-severely-active-ulcerative-colitis 2025-04-30T13:35:04+00:00 hourly 0.9 https://trial.medpath.com/news/honorhealth-launches-first-global-trial-of-novel-t-cell-therapy-targeting-aggressive-melanoma 2025-04-30T13:34:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/honorhealth-launches-first-global-trial-of-novel-t-cell-therapy-targeting-aggressive-melanoma 2025-04-30T13:34:20+00:00 hourly 0.9 https://trial.medpath.com/news/oncocyte-advances-toward-clinical-trial-for-organ-transplant-rejection-test-kit 2025-04-30T13:33:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncocyte-advances-toward-clinical-trial-for-organ-transplant-rejection-test-kit 2025-04-30T13:33:50+00:00 hourly 0.9 https://trial.medpath.com/news/achieve-life-sciences-files-for-fda-approval-of-cytisinicline-first-new-smoking-cessation-drug-in-nearly-20-years 2025-04-30T11:33:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/achieve-life-sciences-files-for-fda-approval-of-cytisinicline-first-new-smoking-cessation-drug-in-nearly-20-years 2025-04-30T11:33:44+00:00 hourly 0.9 https://trial.medpath.com/news/rage-inhibitor-pipeline-shows-promise-for-inflammatory-diseases-with-5-companies-advancing-novel-therapeutics 2025-04-30T11:18:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rage-inhibitor-pipeline-shows-promise-for-inflammatory-diseases-with-5-companies-advancing-novel-therapeutics 2025-04-30T11:18:00+00:00 hourly 0.9 https://trial.medpath.com/news/x-chem-and-orion-pharma-expand-collaboration-to-accelerate-small-molecule-drug-discovery 2025-04-30T10:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/x-chem-and-orion-pharma-expand-collaboration-to-accelerate-small-molecule-drug-discovery 2025-04-30T10:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/bold-therapeutics-presents-breakthrough-data-on-bold-100-s-neuroprotective-effects-at-aacr-2025 2025-04-30T08:53:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bold-therapeutics-presents-breakthrough-data-on-bold-100-s-neuroprotective-effects-at-aacr-2025 2025-04-30T08:53:00+00:00 hourly 0.9 https://trial.medpath.com/news/lantheus-alzheimer-s-radiodiagnostic-mk-6240-achieves-pivotal-study-success-nda-filing-planned 2025-04-30T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lantheus-alzheimer-s-radiodiagnostic-mk-6240-achieves-pivotal-study-success-nda-filing-planned 2025-04-30T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/parp-inhibitor-niraparib-shows-breakthrough-results-in-mesothelioma-treatment 2025-04-30T07:33:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/parp-inhibitor-niraparib-shows-breakthrough-results-in-mesothelioma-treatment 2025-04-30T07:33:42+00:00 hourly 0.9 https://trial.medpath.com/news/trump-s-first-100-days-tariffs-and-workforce-cuts-reshape-healthcare-industry 2025-04-30T07:33:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trump-s-first-100-days-tariffs-and-workforce-cuts-reshape-healthcare-industry 2025-04-30T07:33:35+00:00 hourly 0.9 https://trial.medpath.com/news/apertura-gene-therapy-partners-with-rett-syndrome-research-trust-to-advance-blood-brain-barrier-crossing-gene-therapy-platform 2025-04-30T07:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/apertura-gene-therapy-partners-with-rett-syndrome-research-trust-to-advance-blood-brain-barrier-crossing-gene-therapy-platform 2025-04-30T07:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/sapient-launches-dynamiq-next-generation-multi-omics-platform-set-to-transform-drug-discovery-and-development 2025-04-30T07:14:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sapient-launches-dynamiq-next-generation-multi-omics-platform-set-to-transform-drug-discovery-and-development 2025-04-30T07:14:00+00:00 hourly 0.9 https://trial.medpath.com/news/nodthera-s-nlrp3-inhibitor-nt-0796-shows-enhanced-weight-loss-when-combined-with-glp-1-therapy 2025-04-30T07:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nodthera-s-nlrp3-inhibitor-nt-0796-shows-enhanced-weight-loss-when-combined-with-glp-1-therapy 2025-04-30T07:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/federal-court-dismisses-sanofi-s-appeal-orders-amgen-s-repatha-patent-applications-to-proceed-in-australia 2025-04-30T06:00:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-court-dismisses-sanofi-s-appeal-orders-amgen-s-repatha-patent-applications-to-proceed-in-australia 2025-04-30T06:00:26+00:00 hourly 0.9 https://trial.medpath.com/news/genincode-faces-fda-hurdles-in-de-novo-submission-for-cardiovascular-genetic-risk-assessment 2025-04-30T06:00:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genincode-faces-fda-hurdles-in-de-novo-submission-for-cardiovascular-genetic-risk-assessment 2025-04-30T06:00:11+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-path-for-ingenium-s-nk-cell-therapy-gengleucel-to-enter-phase-2-trials-for-mrd-aml 2025-04-30T05:33:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-path-for-ingenium-s-nk-cell-therapy-gengleucel-to-enter-phase-2-trials-for-mrd-aml 2025-04-30T05:33:00+00:00 hourly 0.9 https://trial.medpath.com/news/trisalus-life-sciences-secures-22-million-private-placement-to-advance-oncology-drug-delivery-platform 2025-04-30T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trisalus-life-sciences-secures-22-million-private-placement-to-advance-oncology-drug-delivery-platform 2025-04-30T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fruquintinib-capecitabine-combination-shows-promise-as-maintenance-therapy-for-ras-braf-wild-type-metastatic-colorectal-cancer 2025-04-30T04:33:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fruquintinib-capecitabine-combination-shows-promise-as-maintenance-therapy-for-ras-braf-wild-type-metastatic-colorectal-cancer 2025-04-30T04:33:33+00:00 hourly 0.9 https://trial.medpath.com/news/low-lung-cancer-screening-rates-in-us-threaten-patient-outcomes-despite-proven-benefits 2025-04-30T02:33:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/low-lung-cancer-screening-rates-in-us-threaten-patient-outcomes-despite-proven-benefits 2025-04-30T02:33:36+00:00 hourly 0.9 https://trial.medpath.com/news/cinclus-pharma-advances-linaprazan-glurate-toward-phase-iii-trials-for-acid-related-diseases 2025-04-30T02:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cinclus-pharma-advances-linaprazan-glurate-toward-phase-iii-trials-for-acid-related-diseases 2025-04-30T02:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/dual-biopsy-approach-significantly-improves-survival-in-advanced-cancer-patients 2025-04-30T01:34:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dual-biopsy-approach-significantly-improves-survival-in-advanced-cancer-patients 2025-04-30T01:34:38+00:00 hourly 0.9 https://trial.medpath.com/news/centivax-secures-45m-series-a-and-cepi-funding-to-advance-universal-influenza-vaccine-platform 2025-04-30T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/centivax-secures-45m-series-a-and-cepi-funding-to-advance-universal-influenza-vaccine-platform 2025-04-30T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/sparc-shares-drop-19-following-failed-psoriasis-drug-trial 2025-04-30T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sparc-shares-drop-19-following-failed-psoriasis-drug-trial 2025-04-30T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/first-comprehensive-post-marketing-safety-comparison-reveals-differing-adverse-event-profiles-for-geographic-atrophy-treatments 2025-04-30T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-comprehensive-post-marketing-safety-comparison-reveals-differing-adverse-event-profiles-for-geographic-atrophy-treatments 2025-04-30T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/groundbreaking-gene-therapy-gives-new-life-to-boy-with-death-sentence-immune-disease 2025-04-29T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/groundbreaking-gene-therapy-gives-new-life-to-boy-with-death-sentence-immune-disease 2025-04-29T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-j-j-s-akeega-for-brca-positive-metastatic-prostate-cancer 2025-04-29T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-j-j-s-akeega-for-brca-positive-metastatic-prostate-cancer 2025-04-29T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/jeffs-brands-divests-u-s-e-commerce-assets-to-canadian-public-company-in-11-8-million-strategic-transaction 2025-04-29T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jeffs-brands-divests-u-s-e-commerce-assets-to-canadian-public-company-in-11-8-million-strategic-transaction 2025-04-29T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/d3s-001-shows-breakthrough-efficacy-as-next-generation-kras-g12c-inhibitor-in-multiple-cancer-types 2025-04-29T23:57:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/d3s-001-shows-breakthrough-efficacy-as-next-generation-kras-g12c-inhibitor-in-multiple-cancer-types 2025-04-29T23:57:26+00:00 hourly 0.9 https://trial.medpath.com/news/new-study-challenges-fda-s-safety-claims-on-mifepristone-prompting-regulatory-scrutiny 2025-04-29T22:33:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-study-challenges-fda-s-safety-claims-on-mifepristone-prompting-regulatory-scrutiny 2025-04-29T22:33:51+00:00 hourly 0.9 https://trial.medpath.com/news/gilead-to-showcase-new-data-on-liver-disease-treatments-at-easl-2025-congress 2025-04-29T22:33:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gilead-to-showcase-new-data-on-liver-disease-treatments-at-easl-2025-congress 2025-04-29T22:33:48+00:00 hourly 0.9 https://trial.medpath.com/news/proofpilot-and-digital-medicine-society-partner-to-develop-digital-tools-for-opioid-use-disorder-prevention 2025-04-29T22:33:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/proofpilot-and-digital-medicine-society-partner-to-develop-digital-tools-for-opioid-use-disorder-prevention 2025-04-29T22:33:47+00:00 hourly 0.9 https://trial.medpath.com/news/rafael-holdings-completes-25-million-rights-offering-to-fund-trappsol-cyclo-phase-3-trial-for-rare-disease 2025-04-29T21:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rafael-holdings-completes-25-million-rights-offering-to-fund-trappsol-cyclo-phase-3-trial-for-rare-disease 2025-04-29T21:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-icam-1-targeting-car-t-cell-therapy-shows-promise-in-advanced-thyroid-cancers 2025-04-29T19:37:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-icam-1-targeting-car-t-cell-therapy-shows-promise-in-advanced-thyroid-cancers 2025-04-29T19:37:57+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-exits-neuroscience-research-to-focus-on-core-therapeutic-areas 2025-04-29T19:37:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-exits-neuroscience-research-to-focus-on-core-therapeutic-areas 2025-04-29T19:37:54+00:00 hourly 0.9 https://trial.medpath.com/news/pharmamar-seeks-eu-fast-track-status-for-lurbinectedin-tecentriq-combination-in-extensive-stage-sclc 2025-04-29T19:37:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharmamar-seeks-eu-fast-track-status-for-lurbinectedin-tecentriq-combination-in-extensive-stage-sclc 2025-04-29T19:37:44+00:00 hourly 0.9 https://trial.medpath.com/news/racial-and-ethnic-disparities-persist-in-pediatric-neuroblastoma-survival-despite-clinical-trial-access 2025-04-29T19:37:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/racial-and-ethnic-disparities-persist-in-pediatric-neuroblastoma-survival-despite-clinical-trial-access 2025-04-29T19:37:27+00:00 hourly 0.9 https://trial.medpath.com/news/central-florida-kidney-specialists-partners-with-clintrial-research-to-advance-nephrology-clinical-trials 2025-04-29T17:35:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/central-florida-kidney-specialists-partners-with-clintrial-research-to-advance-nephrology-clinical-trials 2025-04-29T17:35:07+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-fabhalta-poised-to-transform-treatment-landscape-for-multiple-complement-mediated-diseases 2025-04-29T17:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-fabhalta-poised-to-transform-treatment-landscape-for-multiple-complement-mediated-diseases 2025-04-29T17:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-discontinues-phase-3-trial-of-truqap-for-metastatic-prostate-cancer 2025-04-29T16:40:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-discontinues-phase-3-trial-of-truqap-for-metastatic-prostate-cancer 2025-04-29T16:40:28+00:00 hourly 0.9 https://trial.medpath.com/news/johns-hopkins-medicine-joins-renovorx-s-phase-iii-pancreatic-cancer-trial-as-new-enrollment-site 2025-04-29T16:40:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johns-hopkins-medicine-joins-renovorx-s-phase-iii-pancreatic-cancer-trial-as-new-enrollment-site 2025-04-29T16:40:27+00:00 hourly 0.9 https://trial.medpath.com/news/forecast-2-world-first-trial-uses-tumor-organoids-to-personalize-bowel-cancer-treatment 2025-04-29T16:39:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/forecast-2-world-first-trial-uses-tumor-organoids-to-personalize-bowel-cancer-treatment 2025-04-29T16:39:51+00:00 hourly 0.9 https://trial.medpath.com/news/zyversa-s-ic-100-shows-promise-as-disease-modifying-treatment-for-parkinson-s-disease 2025-04-29T16:39:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zyversa-s-ic-100-shows-promise-as-disease-modifying-treatment-for-parkinson-s-disease 2025-04-29T16:39:07+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-incyclix-bio-s-inx-315-for-ccne1-amplified-platinum-resistant-ovarian-cancer 2025-04-29T16:39:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-fast-track-designation-to-incyclix-bio-s-inx-315-for-ccne1-amplified-platinum-resistant-ovarian-cancer 2025-04-29T16:39:02+00:00 hourly 0.9 https://trial.medpath.com/news/continuity-biosciences-expands-into-aesthetics-with-strategic-investment-in-3d-printed-microneedle-technology 2025-04-29T16:38:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/continuity-biosciences-expands-into-aesthetics-with-strategic-investment-in-3d-printed-microneedle-technology 2025-04-29T16:38:17+00:00 hourly 0.9 https://trial.medpath.com/news/nanoviricides-advances-nv-387-as-potential-treatment-for-measles-amid-declining-vaccination-rates 2025-04-29T16:38:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nanoviricides-advances-nv-387-as-potential-treatment-for-measles-amid-declining-vaccination-rates 2025-04-29T16:38:15+00:00 hourly 0.9 https://trial.medpath.com/news/palatin-s-pl9643-achieves-unprecedented-complete-symptom-resolution-in-dry-eye-disease-phase-3-trial 2025-04-29T16:38:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/palatin-s-pl9643-achieves-unprecedented-complete-symptom-resolution-in-dry-eye-disease-phase-3-trial 2025-04-29T16:38:10+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-in-diabetes-management-first-one-year-cgm-system-integrates-with-automated-insulin-delivery 2025-04-29T16:36:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-in-diabetes-management-first-one-year-cgm-system-integrates-with-automated-insulin-delivery 2025-04-29T16:36:46+00:00 hourly 0.9 https://trial.medpath.com/news/morepen-laboratories-advances-development-of-resmetirom-for-nash-treatment 2025-04-29T16:36:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/morepen-laboratories-advances-development-of-resmetirom-for-nash-treatment 2025-04-29T16:36:19+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-shorla-oncology-s-tepylute-100mg-first-ready-to-dilute-multi-dose-thiotepa-for-breast-and-ovarian-cancer 2025-04-29T16:35:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-shorla-oncology-s-tepylute-100mg-first-ready-to-dilute-multi-dose-thiotepa-for-breast-and-ovarian-cancer 2025-04-29T16:35:20+00:00 hourly 0.9 https://trial.medpath.com/news/fda-budget-cuts-linked-to-drug-approval-delays-as-small-biotech-faces-pdufa-postponement 2025-04-29T16:35:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-budget-cuts-linked-to-drug-approval-delays-as-small-biotech-faces-pdufa-postponement 2025-04-29T16:35:14+00:00 hourly 0.9 https://trial.medpath.com/news/unravel-biosciences-advances-rvl-001-to-clinical-trials-for-rett-and-pitt-hopkins-syndromes-in-colombia 2025-04-29T16:35:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/unravel-biosciences-advances-rvl-001-to-clinical-trials-for-rett-and-pitt-hopkins-syndromes-in-colombia 2025-04-29T16:35:06+00:00 hourly 0.9 https://trial.medpath.com/news/first-patient-enrolled-in-clinical-trial-evaluating-relizorb-for-pancreatitis-patients-with-epi 2025-04-29T16:34:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-patient-enrolled-in-clinical-trial-evaluating-relizorb-for-pancreatitis-patients-with-epi 2025-04-29T16:34:32+00:00 hourly 0.9 https://trial.medpath.com/news/acousia-therapeutics-reaches-50-enrollment-in-phase-2-trial-for-cisplatin-induced-hearing-loss-prevention 2025-04-29T16:34:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/acousia-therapeutics-reaches-50-enrollment-in-phase-2-trial-for-cisplatin-induced-hearing-loss-prevention 2025-04-29T16:34:30+00:00 hourly 0.9 https://trial.medpath.com/news/roosterbio-and-thermo-fisher-scientific-form-strategic-partnership-to-accelerate-cell-and-exosome-therapy-development 2025-04-29T16:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roosterbio-and-thermo-fisher-scientific-form-strategic-partnership-to-accelerate-cell-and-exosome-therapy-development 2025-04-29T16:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/tepylute-a-ready-to-dilute-formulation-of-thiotepa-now-available 2025-04-29T15:46:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tepylute-a-ready-to-dilute-formulation-of-thiotepa-now-available 2025-04-29T15:46:43+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-accelerates-23-billion-us-manufacturing-investment-as-ceo-warns-of-devastating-drug-pricing-controls 2025-04-29T14:04:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-accelerates-23-billion-us-manufacturing-investment-as-ceo-warns-of-devastating-drug-pricing-controls 2025-04-29T14:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-receptor-agonists-show-promise-in-secondary-prevention-of-atrial-fibrillation 2025-04-29T14:03:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glp-1-receptor-agonists-show-promise-in-secondary-prevention-of-atrial-fibrillation 2025-04-29T14:03:55+00:00 hourly 0.9 https://trial.medpath.com/news/atossa-therapeutics-unveils-smart-2-0-study-to-reduce-interval-breast-cancer-in-high-risk-women 2025-04-29T13:35:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/atossa-therapeutics-unveils-smart-2-0-study-to-reduce-interval-breast-cancer-in-high-risk-women 2025-04-29T13:35:58+00:00 hourly 0.9 https://trial.medpath.com/news/novel-btk-inhibitor-combination-shows-promise-in-primary-cns-lymphoma-trial 2025-04-29T13:35:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-btk-inhibitor-combination-shows-promise-in-primary-cns-lymphoma-trial 2025-04-29T13:35:14+00:00 hourly 0.9 https://trial.medpath.com/news/vesicor-therapeutics-to-go-public-via-70m-spac-merger-advancing-novel-p53-cancer-therapy 2025-04-29T13:35:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vesicor-therapeutics-to-go-public-via-70m-spac-merger-advancing-novel-p53-cancer-therapy 2025-04-29T13:35:08+00:00 hourly 0.9 https://trial.medpath.com/news/american-heart-association-awards-1m-to-study-glp-1-medications-impact-on-cardiovascular-risk 2025-04-29T13:35:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/american-heart-association-awards-1m-to-study-glp-1-medications-impact-on-cardiovascular-risk 2025-04-29T13:35:06+00:00 hourly 0.9 https://trial.medpath.com/news/fda-misses-deadline-for-stealth-biotherapeutics-rare-barth-syndrome-drug-elamipretide 2025-04-29T13:34:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-misses-deadline-for-stealth-biotherapeutics-rare-barth-syndrome-drug-elamipretide 2025-04-29T13:34:36+00:00 hourly 0.9 https://trial.medpath.com/news/biomay-receives-fda-approval-for-cas9-nuclease-manufacturing-expanding-crispr-therapy-supply-chain 2025-04-29T13:34:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biomay-receives-fda-approval-for-cas9-nuclease-manufacturing-expanding-crispr-therapy-supply-chain 2025-04-29T13:34:10+00:00 hourly 0.9 https://trial.medpath.com/news/artiva-s-allonk-shows-promising-durability-in-b-cell-non-hodgkin-lymphoma-matching-car-t-efficacy 2025-04-29T13:33:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/artiva-s-allonk-shows-promising-durability-in-b-cell-non-hodgkin-lymphoma-matching-car-t-efficacy 2025-04-29T13:33:59+00:00 hourly 0.9 https://trial.medpath.com/news/chla-pioneers-pig-heart-xenotransplantation-study-for-critically-ill-infants 2025-04-29T13:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chla-pioneers-pig-heart-xenotransplantation-study-for-critically-ill-infants 2025-04-29T13:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-commissioner-assures-drug-review-timelines-will-be-met-despite-mass-layoffs 2025-04-29T12:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-commissioner-assures-drug-review-timelines-will-be-met-despite-mass-layoffs 2025-04-29T12:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/henlius-and-sandoz-partner-on-ipilimumab-biosimilar-in-301-million-deal-to-expand-global-access 2025-04-29T11:38:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/henlius-and-sandoz-partner-on-ipilimumab-biosimilar-in-301-million-deal-to-expand-global-access 2025-04-29T11:38:00+00:00 hourly 0.9 https://trial.medpath.com/news/sangamo-therapeutics-to-showcase-breakthrough-prion-disease-treatment-at-asgct-annual-meeting 2025-04-29T10:34:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sangamo-therapeutics-to-showcase-breakthrough-prion-disease-treatment-at-asgct-annual-meeting 2025-04-29T10:34:50+00:00 hourly 0.9 https://trial.medpath.com/news/shape-therapeutics-to-present-breakthrough-rna-editing-data-for-cns-therapies-at-asgct-annual-meeting 2025-04-29T10:34:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shape-therapeutics-to-present-breakthrough-rna-editing-data-for-cns-therapies-at-asgct-annual-meeting 2025-04-29T10:34:49+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-halts-phase-3-trial-of-capivasertib-for-metastatic-castration-resistant-prostate-cancer 2025-04-29T10:33:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-halts-phase-3-trial-of-capivasertib-for-metastatic-castration-resistant-prostate-cancer 2025-04-29T10:33:51+00:00 hourly 0.9 https://trial.medpath.com/news/dyno-therapeutics-unveils-three-ai-designed-aav-capsids-for-enhanced-gene-therapy-delivery 2025-04-29T10:33:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dyno-therapeutics-unveils-three-ai-designed-aav-capsids-for-enhanced-gene-therapy-delivery 2025-04-29T10:33:42+00:00 hourly 0.9 https://trial.medpath.com/news/kytopen-forges-strategic-partnerships-to-revolutionize-cell-therapy-manufacturing-with-non-viral-engineering-platform 2025-04-29T10:07:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kytopen-forges-strategic-partnerships-to-revolutionize-cell-therapy-manufacturing-with-non-viral-engineering-platform 2025-04-29T10:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/therini-bio-s-thn391-shows-promise-in-phase-1a-trial-for-neurodegenerative-diseases 2025-04-29T10:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/therini-bio-s-thn391-shows-promise-in-phase-1a-trial-for-neurodegenerative-diseases 2025-04-29T10:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fate-therapeutics-to-showcase-innovative-off-the-shelf-car-t-cell-platform-at-asgct-annual-meeting 2025-04-29T09:25:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fate-therapeutics-to-showcase-innovative-off-the-shelf-car-t-cell-platform-at-asgct-annual-meeting 2025-04-29T09:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/tempus-introduces-xm-liquid-biopsy-assay-to-monitor-immunotherapy-response-in-advanced-solid-tumors 2025-04-29T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tempus-introduces-xm-liquid-biopsy-assay-to-monitor-immunotherapy-response-in-advanced-solid-tumors 2025-04-29T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/oncocyte-s-blood-based-transplant-rejection-assay-shows-long-term-clinical-validity-in-13-year-study 2025-04-29T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncocyte-s-blood-based-transplant-rejection-assay-shows-long-term-clinical-validity-in-13-year-study 2025-04-29T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/alxn1840-shows-promising-long-term-efficacy-and-safety-for-wilson-disease-at-easl-2025 2025-04-29T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alxn1840-shows-promising-long-term-efficacy-and-safety-for-wilson-disease-at-easl-2025 2025-04-29T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/prometheus-laboratories-unveils-groundbreaking-pre-therapy-test-for-ibd-biologic-response-prediction 2025-04-29T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prometheus-laboratories-unveils-groundbreaking-pre-therapy-test-for-ibd-biologic-response-prediction 2025-04-29T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bdr-pharmaceuticals-plans-100-million-u-s-expansion-to-boost-global-footprint 2025-04-29T07:33:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bdr-pharmaceuticals-plans-100-million-u-s-expansion-to-boost-global-footprint 2025-04-29T07:33:32+00:00 hourly 0.9 https://trial.medpath.com/news/scaleready-awards-g-rex-grants-to-advance-novel-car-t-cell-therapy-manufacturing 2025-04-29T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scaleready-awards-g-rex-grants-to-advance-novel-car-t-cell-therapy-manufacturing 2025-04-29T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/first-patient-dosed-with-psv359-in-perspective-therapeutics-phase-1-2a-trial-for-fap-a-positive-solid-tumors 2025-04-29T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-patient-dosed-with-psv359-in-perspective-therapeutics-phase-1-2a-trial-for-fap-a-positive-solid-tumors 2025-04-29T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/flatiron-health-to-showcase-ai-powered-real-world-oncology-data-research-at-ispor-2025 2025-04-29T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/flatiron-health-to-showcase-ai-powered-real-world-oncology-data-research-at-ispor-2025 2025-04-29T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/community-engagement-emerges-as-critical-bridge-between-cancer-research-and-policy-development 2025-04-29T05:03:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/community-engagement-emerges-as-critical-bridge-between-cancer-research-and-policy-development 2025-04-29T05:03:35+00:00 hourly 0.9 https://trial.medpath.com/news/paradigm-shift-in-iga-nephropathy-treatment-novel-targeted-therapies-address-disease-mechanisms 2025-04-29T02:33:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/paradigm-shift-in-iga-nephropathy-treatment-novel-targeted-therapies-address-disease-mechanisms 2025-04-29T02:33:54+00:00 hourly 0.9 https://trial.medpath.com/news/personalized-treatment-approaches-for-relapsed-refractory-follicular-lymphoma-navigating-third-line-therapy-options 2025-04-29T02:33:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/personalized-treatment-approaches-for-relapsed-refractory-follicular-lymphoma-navigating-third-line-therapy-options 2025-04-29T02:33:41+00:00 hourly 0.9 https://trial.medpath.com/news/pacira-s-gene-therapy-demonstrates-sustained-efficacy-in-knee-osteoarthritis-trial 2025-04-29T01:56:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pacira-s-gene-therapy-demonstrates-sustained-efficacy-in-knee-osteoarthritis-trial 2025-04-29T01:56:45+00:00 hourly 0.9 https://trial.medpath.com/news/embark-trial-testosterone-levels-recover-in-most-men-after-prostate-cancer-treatment-suspension 2025-04-29T01:33:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/embark-trial-testosterone-levels-recover-in-most-men-after-prostate-cancer-treatment-suspension 2025-04-29T01:33:43+00:00 hourly 0.9 https://trial.medpath.com/news/stablepharma-begins-phase-1-trial-of-world-s-first-fridge-free-tetanus-diphtheria-vaccine 2025-04-29T01:33:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stablepharma-begins-phase-1-trial-of-world-s-first-fridge-free-tetanus-diphtheria-vaccine 2025-04-29T01:33:41+00:00 hourly 0.9 https://trial.medpath.com/news/deepull-raises-eur50-million-in-series-c-to-advance-rapid-sepsis-diagnostic-technology 2025-04-29T00:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/deepull-raises-eur50-million-in-series-c-to-advance-rapid-sepsis-diagnostic-technology 2025-04-29T00:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/cantargia-expands-can10-development-to-target-treatment-resistant-atopic-dermatitis 2025-04-29T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cantargia-expands-can10-development-to-target-treatment-resistant-atopic-dermatitis 2025-04-29T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/acc-recommends-first-line-obesity-medications-as-prescribing-disparities-persist-for-semaglutide-and-tirzepatide 2025-04-29T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/acc-recommends-first-line-obesity-medications-as-prescribing-disparities-persist-for-semaglutide-and-tirzepatide 2025-04-29T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/capsida-biotherapeutics-advances-novel-gene-therapies-for-cns-disorders-ahead-of-asgct-2025 2025-04-29T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/capsida-biotherapeutics-advances-novel-gene-therapies-for-cns-disorders-ahead-of-asgct-2025 2025-04-29T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-bioinvent-s-bi-1808-for-cutaneous-t-cell-lymphoma 2025-04-29T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-fast-track-designation-to-bioinvent-s-bi-1808-for-cutaneous-t-cell-lymphoma 2025-04-29T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fyr-partners-with-mayo-clinic-to-develop-blood-based-biomarkers-for-parkinson-s-disease-using-ai-enabled-platform 2025-04-29T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fyr-partners-with-mayo-clinic-to-develop-blood-based-biomarkers-for-parkinson-s-disease-using-ai-enabled-platform 2025-04-29T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-car-t-cell-therapy-shows-100-response-rate-in-refractory-cd30-lymphoma-patients 2025-04-29T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-car-t-cell-therapy-shows-100-response-rate-in-refractory-cd30-lymphoma-patients 2025-04-29T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/invikafusp-alfa-demonstrates-promising-activity-in-immune-checkpoint-inhibitor-resistant-solid-tumors 2025-04-29T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/invikafusp-alfa-demonstrates-promising-activity-in-immune-checkpoint-inhibitor-resistant-solid-tumors 2025-04-29T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/transverse-medical-secures-over-10m-in-series-b2-funding-to-advance-stroke-prevention-technology 2025-04-29T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/transverse-medical-secures-over-10m-in-series-b2-funding-to-advance-stroke-prevention-technology 2025-04-29T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/frontier-medicines-presents-breakthrough-data-on-fmc-220-first-in-class-p53-y220c-activator-for-cancer-treatment 2025-04-28T22:35:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/frontier-medicines-presents-breakthrough-data-on-fmc-220-first-in-class-p53-y220c-activator-for-cancer-treatment 2025-04-28T22:35:30+00:00 hourly 0.9 https://trial.medpath.com/news/oramed-pharmaceuticals-invests-36-9-million-in-alpha-tau-medical-to-advance-cancer-radiation-therapy 2025-04-28T22:35:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oramed-pharmaceuticals-invests-36-9-million-in-alpha-tau-medical-to-advance-cancer-radiation-therapy 2025-04-28T22:35:29+00:00 hourly 0.9 https://trial.medpath.com/news/world-first-immunotherapy-trial-aims-to-reprogram-immune-system-in-type-1-diabetes 2025-04-28T22:34:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/world-first-immunotherapy-trial-aims-to-reprogram-immune-system-in-type-1-diabetes 2025-04-28T22:34:46+00:00 hourly 0.9 https://trial.medpath.com/news/j-j-s-tar-200-shows-promising-results-in-bcg-unresponsive-bladder-cancer-trial 2025-04-28T22:34:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/j-j-s-tar-200-shows-promising-results-in-bcg-unresponsive-bladder-cancer-trial 2025-04-28T22:34:45+00:00 hourly 0.9 https://trial.medpath.com/news/michigan-senate-approves-prescription-drug-affordability-board-to-combat-rising-medication-costs 2025-04-28T21:08:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/michigan-senate-approves-prescription-drug-affordability-board-to-combat-rising-medication-costs 2025-04-28T21:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/scholar-rock-appoints-david-l-hallal-as-ceo-strengthens-leadership-team-ahead-of-apitegromab-launch-for-sma 2025-04-28T20:06:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scholar-rock-appoints-david-l-hallal-as-ceo-strengthens-leadership-team-ahead-of-apitegromab-launch-for-sma 2025-04-28T20:06:12+00:00 hourly 0.9 https://trial.medpath.com/news/histosonics-histotripsy-system-achieves-90-local-tumor-control-at-12-months-in-liver-cancer-trials 2025-04-28T20:06:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/histosonics-histotripsy-system-achieves-90-local-tumor-control-at-12-months-in-liver-cancer-trials 2025-04-28T20:06:10+00:00 hourly 0.9 https://trial.medpath.com/news/immunotherapy-breakthrough-could-replace-traditional-cancer-treatments-in-select-patients 2025-04-28T20:04:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunotherapy-breakthrough-could-replace-traditional-cancer-treatments-in-select-patients 2025-04-28T20:04:04+00:00 hourly 0.9 https://trial.medpath.com/news/redhill-biopharma-secures-key-chinese-patent-for-covid-19-treatment-rhb-107 2025-04-28T19:35:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/redhill-biopharma-secures-key-chinese-patent-for-covid-19-treatment-rhb-107 2025-04-28T19:35:23+00:00 hourly 0.9 https://trial.medpath.com/news/pharmasyntez-to-launch-three-innovative-drugs-with-blockbuster-potential-in-2025-2026 2025-04-28T19:33:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharmasyntez-to-launch-three-innovative-drugs-with-blockbuster-potential-in-2025-2026 2025-04-28T19:33:58+00:00 hourly 0.9 https://trial.medpath.com/news/dr-reddy-s-to-launch-sanofi-s-beyfortus-in-india-for-rsv-prevention-in-infants 2025-04-28T19:33:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dr-reddy-s-to-launch-sanofi-s-beyfortus-in-india-for-rsv-prevention-in-infants 2025-04-28T19:33:56+00:00 hourly 0.9 https://trial.medpath.com/news/cg-oncology-s-bladder-cancer-drug-shows-promising-durability-in-phase-3-trial 2025-04-28T19:33:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cg-oncology-s-bladder-cancer-drug-shows-promising-durability-in-phase-3-trial 2025-04-28T19:33:53+00:00 hourly 0.9 https://trial.medpath.com/news/yale-s-experimental-cancer-vaccine-shows-remarkable-success-in-canine-clinical-trials 2025-04-28T19:33:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/yale-s-experimental-cancer-vaccine-shows-remarkable-success-in-canine-clinical-trials 2025-04-28T19:33:42+00:00 hourly 0.9 https://trial.medpath.com/news/ankyra-therapeutics-reports-promising-phase-1-data-for-anchored-il-12-drug-conjugate-in-solid-tumors 2025-04-28T19:33:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ankyra-therapeutics-reports-promising-phase-1-data-for-anchored-il-12-drug-conjugate-in-solid-tumors 2025-04-28T19:33:30+00:00 hourly 0.9 https://trial.medpath.com/news/g8-frailty-assessment-tool-predicts-docetaxel-tolerability-in-metastatic-prostate-cancer 2025-04-28T19:00:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/g8-frailty-assessment-tool-predicts-docetaxel-tolerability-in-metastatic-prostate-cancer 2025-04-28T19:00:24+00:00 hourly 0.9 https://trial.medpath.com/news/novel-ai-model-progrxn-bca-significantly-improves-nmibc-progression-risk-prediction 2025-04-28T18:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-ai-model-progrxn-bca-significantly-improves-nmibc-progression-risk-prediction 2025-04-28T18:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bms-986365-shows-promise-in-phase-3-trial-for-advanced-prostate-cancer-resistant-to-standard-therapies 2025-04-28T16:51:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bms-986365-shows-promise-in-phase-3-trial-for-advanced-prostate-cancer-resistant-to-standard-therapies 2025-04-28T16:51:00+00:00 hourly 0.9 https://trial.medpath.com/news/theralase-s-ruvidar-shows-promise-as-dub-inhibitor-in-cancer-treatment-breakthrough 2025-04-28T16:36:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/theralase-s-ruvidar-shows-promise-as-dub-inhibitor-in-cancer-treatment-breakthrough 2025-04-28T16:36:52+00:00 hourly 0.9 https://trial.medpath.com/news/neoadjuvant-immunochemotherapy-shows-promising-results-in-locally-advanced-oral-squamous-cell-carcinoma 2025-04-28T16:36:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neoadjuvant-immunochemotherapy-shows-promising-results-in-locally-advanced-oral-squamous-cell-carcinoma 2025-04-28T16:36:21+00:00 hourly 0.9 https://trial.medpath.com/news/tempus-unveils-loop-ai-powered-platform-revolutionizes-oncology-target-discovery 2025-04-28T16:35:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tempus-unveils-loop-ai-powered-platform-revolutionizes-oncology-target-discovery 2025-04-28T16:35:44+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-delcath-s-hepzato-for-phase-2-trial-in-liver-dominant-metastatic-breast-cancer 2025-04-28T16:35:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-delcath-s-hepzato-for-phase-2-trial-in-liver-dominant-metastatic-breast-cancer 2025-04-28T16:35:23+00:00 hourly 0.9 https://trial.medpath.com/news/be-biopharma-to-present-promising-nonclinical-data-for-novel-b-cell-therapy-in-hypophosphatasia-treatment 2025-04-28T16:35:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/be-biopharma-to-present-promising-nonclinical-data-for-novel-b-cell-therapy-in-hypophosphatasia-treatment 2025-04-28T16:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/metrion-biosciences-unveils-breakthrough-nav1-9-screening-assay-to-accelerate-non-opioid-pain-therapeutics-development 2025-04-28T16:34:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/metrion-biosciences-unveils-breakthrough-nav1-9-screening-assay-to-accelerate-non-opioid-pain-therapeutics-development 2025-04-28T16:34:49+00:00 hourly 0.9 https://trial.medpath.com/news/celltrion-to-present-new-zymfentra-r-data-for-ibd-management-at-2025-digestive-disease-week 2025-04-28T16:34:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/celltrion-to-present-new-zymfentra-r-data-for-ibd-management-at-2025-digestive-disease-week 2025-04-28T16:34:32+00:00 hourly 0.9 https://trial.medpath.com/news/kura-oncology-initiates-phase-1-trial-combining-ziftomenib-with-imatinib-for-advanced-gist-treatment 2025-04-28T16:34:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kura-oncology-initiates-phase-1-trial-combining-ziftomenib-with-imatinib-for-advanced-gist-treatment 2025-04-28T16:34:02+00:00 hourly 0.9 https://trial.medpath.com/news/cellectis-advances-gene-editing-with-non-viral-talen-technology-and-tale-base-editors-at-asgct-2025 2025-04-28T16:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cellectis-advances-gene-editing-with-non-viral-talen-technology-and-tale-base-editors-at-asgct-2025 2025-04-28T16:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/spero-therapeutics-appoints-esther-rajavelu-as-president-and-chief-executive-officer 2025-04-28T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spero-therapeutics-appoints-esther-rajavelu-as-president-and-chief-executive-officer 2025-04-28T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/anthem-blue-cross-and-blue-shield-approves-coverage-for-reactiv8-neurostimulation-therapy-for-chronic-low-back-pain 2025-04-28T15:23:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/anthem-blue-cross-and-blue-shield-approves-coverage-for-reactiv8-neurostimulation-therapy-for-chronic-low-back-pain 2025-04-28T15:23:00+00:00 hourly 0.9 https://trial.medpath.com/news/tg-c-shows-promise-as-first-disease-modifying-therapy-for-knee-osteoarthritis-with-15-year-safety-data 2025-04-28T15:12:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tg-c-shows-promise-as-first-disease-modifying-therapy-for-knee-osteoarthritis-with-15-year-safety-data 2025-04-28T15:12:00+00:00 hourly 0.9 https://trial.medpath.com/news/samsung-biologics-surpasses-2-2-billion-in-2025-contract-orders-expands-global-biomanufacturing-capacity 2025-04-28T14:47:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/samsung-biologics-surpasses-2-2-billion-in-2025-contract-orders-expands-global-biomanufacturing-capacity 2025-04-28T14:47:00+00:00 hourly 0.9 https://trial.medpath.com/news/merck-kgaa-to-acquire-springworks-therapeutics-in-3-9-billion-deal-for-rare-disease-portfolio 2025-04-28T14:37:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-kgaa-to-acquire-springworks-therapeutics-in-3-9-billion-deal-for-rare-disease-portfolio 2025-04-28T14:37:28+00:00 hourly 0.9 https://trial.medpath.com/news/medicus-pharma-to-acquire-antev-for-75-million-gaining-novel-gnrh-antagonist-for-prostate-conditions 2025-04-28T14:37:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medicus-pharma-to-acquire-antev-for-75-million-gaining-novel-gnrh-antagonist-for-prostate-conditions 2025-04-28T14:37:25+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approved-lenire-device-shows-91-5-success-rate-in-real-world-tinnitus-treatment-study 2025-04-28T14:37:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approved-lenire-device-shows-91-5-success-rate-in-real-world-tinnitus-treatment-study 2025-04-28T14:37:19+00:00 hourly 0.9 https://trial.medpath.com/news/biohaven-secures-600-million-non-dilutive-funding-from-oberland-capital-for-rare-disease-drug-development 2025-04-28T14:36:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biohaven-secures-600-million-non-dilutive-funding-from-oberland-capital-for-rare-disease-drug-development 2025-04-28T14:36:50+00:00 hourly 0.9 https://trial.medpath.com/news/talus-bio-unveils-promising-preclinical-data-on-novel-transcription-factor-inhibitors-at-aacr-2025 2025-04-28T13:44:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/talus-bio-unveils-promising-preclinical-data-on-novel-transcription-factor-inhibitors-at-aacr-2025 2025-04-28T13:44:04+00:00 hourly 0.9 https://trial.medpath.com/news/new-biomarker-for-early-parkinson-s-detection-shows-over-90-accuracy-in-clinical-trials 2025-04-28T13:42:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-biomarker-for-early-parkinson-s-detection-shows-over-90-accuracy-in-clinical-trials 2025-04-28T13:42:11+00:00 hourly 0.9 https://trial.medpath.com/news/purespring-s-ps-002-receives-ema-orphan-drug-designation-for-iga-nephropathy-treatment 2025-04-28T13:42:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/purespring-s-ps-002-receives-ema-orphan-drug-designation-for-iga-nephropathy-treatment 2025-04-28T13:42:09+00:00 hourly 0.9 https://trial.medpath.com/news/immvira-reports-favorable-safety-profile-for-oncolytic-virus-mvr-c5252-in-phase-i-glioma-trial 2025-04-28T13:42:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immvira-reports-favorable-safety-profile-for-oncolytic-virus-mvr-c5252-in-phase-i-glioma-trial 2025-04-28T13:42:06+00:00 hourly 0.9 https://trial.medpath.com/news/galmed-pharmaceuticals-advances-novel-sublingual-semaglutide-formulation-to-challenge-injectable-glp-1-market 2025-04-28T13:40:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/galmed-pharmaceuticals-advances-novel-sublingual-semaglutide-formulation-to-challenge-injectable-glp-1-market 2025-04-28T13:40:48+00:00 hourly 0.9 https://trial.medpath.com/news/pretomanid-price-drops-25-boosting-access-to-life-saving-tb-treatment-across-africa 2025-04-28T13:40:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pretomanid-price-drops-25-boosting-access-to-life-saving-tb-treatment-across-africa 2025-04-28T13:40:47+00:00 hourly 0.9 https://trial.medpath.com/news/thermo-fisher-scientific-commits-2-billion-to-expand-us-manufacturing-and-r-d-capabilities 2025-04-28T13:40:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/thermo-fisher-scientific-commits-2-billion-to-expand-us-manufacturing-and-r-d-capabilities 2025-04-28T13:40:11+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-adma-biologics-innovative-yield-enhancement-process-for-immune-globulin-production 2025-04-28T13:39:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-adma-biologics-innovative-yield-enhancement-process-for-immune-globulin-production 2025-04-28T13:39:40+00:00 hourly 0.9 https://trial.medpath.com/news/pci-pharma-services-to-acquire-ajinomoto-althea-expanding-us-fill-finish-capabilities 2025-04-28T13:39:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pci-pharma-services-to-acquire-ajinomoto-althea-expanding-us-fill-finish-capabilities 2025-04-28T13:39:05+00:00 hourly 0.9 https://trial.medpath.com/news/strand-therapeutics-unveils-promising-preclinical-data-for-stx-003-mrna-therapy-targeting-solid-tumors 2025-04-28T13:35:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/strand-therapeutics-unveils-promising-preclinical-data-for-stx-003-mrna-therapy-targeting-solid-tumors 2025-04-28T13:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/guardant-health-launches-first-tissue-test-with-comprehensive-multiomic-analysis-for-cancer-profiling 2025-04-28T13:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/guardant-health-launches-first-tissue-test-with-comprehensive-multiomic-analysis-for-cancer-profiling 2025-04-28T13:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/revolution-medicines-reports-promising-results-for-zoldonrasib-in-kras-g12d-mutant-lung-cancer 2025-04-28T11:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/revolution-medicines-reports-promising-results-for-zoldonrasib-in-kras-g12d-mutant-lung-cancer 2025-04-28T11:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/brain-navi-partners-with-first-securities-for-ipo-aims-to-accelerate-global-medtech-expansion 2025-04-28T10:34:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brain-navi-partners-with-first-securities-for-ipo-aims-to-accelerate-global-medtech-expansion 2025-04-28T10:34:33+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-blackfinbio-s-novel-gene-therapy-trial-for-rare-childhood-neurological-disease-spg47 2025-04-28T10:34:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-blackfinbio-s-novel-gene-therapy-trial-for-rare-childhood-neurological-disease-spg47 2025-04-28T10:34:31+00:00 hourly 0.9 https://trial.medpath.com/news/radspherin-r-shows-promising-18-month-results-in-ovarian-cancer-trial-with-90-recurrence-free-rate 2025-04-28T10:33:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/radspherin-r-shows-promising-18-month-results-in-ovarian-cancer-trial-with-90-recurrence-free-rate 2025-04-28T10:33:30+00:00 hourly 0.9 https://trial.medpath.com/news/prilenia-and-ferrer-form-eur500-million-partnership-to-commercialize-pridopidine-for-huntington-s-disease-in-europe 2025-04-28T08:04:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prilenia-and-ferrer-form-eur500-million-partnership-to-commercialize-pridopidine-for-huntington-s-disease-in-europe 2025-04-28T08:04:16+00:00 hourly 0.9 https://trial.medpath.com/news/telix-pharmaceuticals-faces-fda-setback-for-brain-cancer-imaging-agent 2025-04-28T07:34:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/telix-pharmaceuticals-faces-fda-setback-for-brain-cancer-imaging-agent 2025-04-28T07:34:23+00:00 hourly 0.9 https://trial.medpath.com/news/senti-bio-s-logic-gated-car-nk-cell-therapy-shows-promising-results-in-aml-clinical-trial 2025-04-28T07:34:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/senti-bio-s-logic-gated-car-nk-cell-therapy-shows-promising-results-in-aml-clinical-trial 2025-04-28T07:34:20+00:00 hourly 0.9 https://trial.medpath.com/news/monte-rosa-presents-promising-preclinical-data-for-cdk2-molecular-glue-degrader-in-hr-positive-breast-cancer-at-aacr-2025 2025-04-28T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/monte-rosa-presents-promising-preclinical-data-for-cdk2-molecular-glue-degrader-in-hr-positive-breast-cancer-at-aacr-2025 2025-04-28T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/total-telcom-subsidiary-secures-100000-plus-royalties-in-strategic-licensing-deal-for-heater-controllers 2025-04-28T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/total-telcom-subsidiary-secures-100000-plus-royalties-in-strategic-licensing-deal-for-heater-controllers 2025-04-28T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/elpis-biopharmaceuticals-advances-multi-mechanism-armored-car-t-platform-for-solid-tumors 2025-04-28T05:33:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elpis-biopharmaceuticals-advances-multi-mechanism-armored-car-t-platform-for-solid-tumors 2025-04-28T05:33:00+00:00 hourly 0.9 https://trial.medpath.com/news/y-mabs-presents-preclinical-pharmacokinetics-data-for-cd38-sada-pretargeted-radioimmunotherapy-at-aacr-2025 2025-04-28T04:36:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/y-mabs-presents-preclinical-pharmacokinetics-data-for-cd38-sada-pretargeted-radioimmunotherapy-at-aacr-2025 2025-04-28T04:36:18+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-presents-promising-preclinical-data-on-novel-mesothelin-targeting-adc-at-aacr-2025 2025-04-28T04:34:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-presents-promising-preclinical-data-on-novel-mesothelin-targeting-adc-at-aacr-2025 2025-04-28T04:34:59+00:00 hourly 0.9 https://trial.medpath.com/news/advanced-biological-aging-linked-to-30-higher-dementia-risk-new-study-finds 2025-04-28T03:44:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/advanced-biological-aging-linked-to-30-higher-dementia-risk-new-study-finds 2025-04-28T03:44:21+00:00 hourly 0.9 https://trial.medpath.com/news/depression-rates-surge-60-over-past-decade-new-nchs-data-reveals 2025-04-28T03:39:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/depression-rates-surge-60-over-past-decade-new-nchs-data-reveals 2025-04-28T03:39:48+00:00 hourly 0.9 https://trial.medpath.com/news/fda-announces-comprehensive-ban-on-petroleum-based-food-dyes-by-2026 2025-04-28T03:39:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-announces-comprehensive-ban-on-petroleum-based-food-dyes-by-2026 2025-04-28T03:39:46+00:00 hourly 0.9 https://trial.medpath.com/news/fda-confirms-proteinuria-as-primary-endpoint-for-dimerix-s-dmx-200-phase-3-fsgs-trial 2025-04-28T01:33:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-confirms-proteinuria-as-primary-endpoint-for-dimerix-s-dmx-200-phase-3-fsgs-trial 2025-04-28T01:33:47+00:00 hourly 0.9 https://trial.medpath.com/news/fakeeh-care-inks-mou-with-fosun-pharma-to-develop-cell-gene-therapies 2025-04-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fakeeh-care-inks-mou-with-fosun-pharma-to-develop-cell-gene-therapies 2025-04-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/uk-performs-first-easee-brain-implant-surgery-for-drug-resistant-epilepsy-at-newcastle-hospitals 2025-04-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-performs-first-easee-brain-implant-surgery-for-drug-resistant-epilepsy-at-newcastle-hospitals 2025-04-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/national-lipid-association-advocates-for-universal-lipoprotein-a-testing-to-enhance-cardiovascular-risk-assessment 2025-04-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/national-lipid-association-advocates-for-universal-lipoprotein-a-testing-to-enhance-cardiovascular-risk-assessment 2025-04-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/liberty-gold-ceo-cal-everett-retires-after-eight-years-dr-jon-gilligan-named-new-president-and-ceo 2025-04-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/liberty-gold-ceo-cal-everett-retires-after-eight-years-dr-jon-gilligan-named-new-president-and-ceo 2025-04-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/medicare-coverage-of-glp-1-obesity-drugs-could-add-47-7-billion-to-federal-spending-over-10-years 2025-04-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medicare-coverage-of-glp-1-obesity-drugs-could-add-47-7-billion-to-federal-spending-over-10-years 2025-04-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-gene-therapy-targeting-cav-1-protein-shows-promise-in-preserving-memory-function-in-alzheimer-s-disease 2025-04-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-gene-therapy-targeting-cav-1-protein-shows-promise-in-preserving-memory-function-in-alzheimer-s-disease 2025-04-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/y-mabs-initiates-phase-1-trial-of-cd38-sada-radioimmunotherapy-for-relapsed-non-hodgkin-lymphoma 2025-04-27T22:37:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/y-mabs-initiates-phase-1-trial-of-cd38-sada-radioimmunotherapy-for-relapsed-non-hodgkin-lymphoma 2025-04-27T22:37:20+00:00 hourly 0.9 https://trial.medpath.com/news/precede-biosciences-unveils-breakthrough-liquid-biopsy-platform-for-tumor-gene-expression-at-aacr-2025 2025-04-27T22:36:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/precede-biosciences-unveils-breakthrough-liquid-biopsy-platform-for-tumor-gene-expression-at-aacr-2025 2025-04-27T22:36:46+00:00 hourly 0.9 https://trial.medpath.com/news/zealand-pharma-considers-accelerating-obesity-drug-launch-following-landmark-roche-partnership 2025-04-27T22:36:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zealand-pharma-considers-accelerating-obesity-drug-launch-following-landmark-roche-partnership 2025-04-27T22:36:38+00:00 hourly 0.9 https://trial.medpath.com/news/novel-off-the-shelf-car-nk-cell-therapy-shows-complete-remission-in-relapsed-aml-patients 2025-04-27T22:36:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-off-the-shelf-car-nk-cell-therapy-shows-complete-remission-in-relapsed-aml-patients 2025-04-27T22:36:35+00:00 hourly 0.9 https://trial.medpath.com/news/novel-topical-gel-successfully-treats-painful-skin-rash-from-colorectal-cancer-therapy 2025-04-27T22:36:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-topical-gel-successfully-treats-painful-skin-rash-from-colorectal-cancer-therapy 2025-04-27T22:36:32+00:00 hourly 0.9 https://trial.medpath.com/news/abpro-and-celltrion-s-abp-102-ct-p72-shows-promise-as-best-in-class-her2-t-cell-engager 2025-04-27T19:34:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abpro-and-celltrion-s-abp-102-ct-p72-shows-promise-as-best-in-class-her2-t-cell-engager 2025-04-27T19:34:46+00:00 hourly 0.9 https://trial.medpath.com/news/abbott-s-groundbreaking-aveir-leadless-pacemaker-shows-promise-in-first-in-human-conduction-system-pacing-study 2025-04-27T19:33:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbott-s-groundbreaking-aveir-leadless-pacemaker-shows-promise-in-first-in-human-conduction-system-pacing-study 2025-04-27T19:33:58+00:00 hourly 0.9 https://trial.medpath.com/news/immunotherapy-alone-successfully-treats-multiple-cancer-types-with-mmrd-mutation-eliminating-need-for-surgery 2025-04-27T19:33:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunotherapy-alone-successfully-treats-multiple-cancer-types-with-mmrd-mutation-eliminating-need-for-surgery 2025-04-27T19:33:47+00:00 hourly 0.9 https://trial.medpath.com/news/dostarlimab-shows-promise-in-eliminating-need-for-surgery-across-multiple-dmmr-cancer-types 2025-04-27T19:33:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dostarlimab-shows-promise-in-eliminating-need-for-surgery-across-multiple-dmmr-cancer-types 2025-04-27T19:33:39+00:00 hourly 0.9 https://trial.medpath.com/news/immunotherapy-breakthrough-pembrolizumab-doubles-disease-free-survival-in-locally-advanced-head-and-neck-cancer 2025-04-27T19:33:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunotherapy-breakthrough-pembrolizumab-doubles-disease-free-survival-in-locally-advanced-head-and-neck-cancer 2025-04-27T19:33:38+00:00 hourly 0.9 https://trial.medpath.com/news/springworks-anticipates-chmp-opinion-on-nirogacestat-for-desmoid-tumors-in-q2-2025 2025-04-27T16:34:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/springworks-anticipates-chmp-opinion-on-nirogacestat-for-desmoid-tumors-in-q2-2025 2025-04-27T16:34:07+00:00 hourly 0.9 https://trial.medpath.com/news/uniphar-launches-10th-cell-and-gene-therapy-project-expanding-global-access-to-advanced-treatments 2025-04-27T13:33:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uniphar-launches-10th-cell-and-gene-therapy-project-expanding-global-access-to-advanced-treatments 2025-04-27T13:33:38+00:00 hourly 0.9 https://trial.medpath.com/news/zenflow-s-spring-system-shows-durable-three-year-benefits-for-bph-patients-in-landmark-study 2025-04-27T13:33:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zenflow-s-spring-system-shows-durable-three-year-benefits-for-bph-patients-in-landmark-study 2025-04-27T13:33:27+00:00 hourly 0.9 https://trial.medpath.com/news/abbott-s-volt-pfa-system-shows-impressive-12-month-results-for-atrial-fibrillation-treatment 2025-04-27T10:33:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbott-s-volt-pfa-system-shows-impressive-12-month-results-for-atrial-fibrillation-treatment 2025-04-27T10:33:37+00:00 hourly 0.9 https://trial.medpath.com/news/atezolizumab-shows-improved-survival-in-newly-diagnosed-glioblastoma-patients-with-high-immune-infiltration 2025-04-27T07:34:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/atezolizumab-shows-improved-survival-in-newly-diagnosed-glioblastoma-patients-with-high-immune-infiltration 2025-04-27T07:34:18+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-gras-status-to-bestzyme-s-melliatm-brazzein-advancing-zero-calorie-sweetener-market 2025-04-27T04:33:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-gras-status-to-bestzyme-s-melliatm-brazzein-advancing-zero-calorie-sweetener-market 2025-04-27T04:33:38+00:00 hourly 0.9 https://trial.medpath.com/news/medtronic-s-afferatm-pfa-technologies-show-promising-results-for-atrial-fibrillation-treatment 2025-04-27T02:04:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medtronic-s-afferatm-pfa-technologies-show-promising-results-for-atrial-fibrillation-treatment 2025-04-27T02:04:05+00:00 hourly 0.9 https://trial.medpath.com/news/lee-health-heart-institute-reaches-100-patient-milestone-in-global-leapps-stroke-prevention-trial 2025-04-27T01:33:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lee-health-heart-institute-reaches-100-patient-milestone-in-global-leapps-stroke-prevention-trial 2025-04-27T01:33:52+00:00 hourly 0.9 https://trial.medpath.com/news/structured-linezolid-dose-reduction-shows-promise-in-drug-resistant-tb-treatment 2025-04-27T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/structured-linezolid-dose-reduction-shows-promise-in-drug-resistant-tb-treatment 2025-04-27T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/india-launches-first-indigenous-hpv-test-kits-for-cervical-cancer-screening 2025-04-26T22:34:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-launches-first-indigenous-hpv-test-kits-for-cervical-cancer-screening 2025-04-26T22:34:30+00:00 hourly 0.9 https://trial.medpath.com/news/lifitegrast-shows-long-term-safety-and-efficacy-for-dry-eye-disease-in-7-year-analysis 2025-04-26T22:34:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lifitegrast-shows-long-term-safety-and-efficacy-for-dry-eye-disease-in-7-year-analysis 2025-04-26T22:34:22+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-trofinetide-as-first-ever-treatment-for-rett-syndrome-opening-new-era-for-rare-genetic-disorder 2025-04-26T22:34:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-trofinetide-as-first-ever-treatment-for-rett-syndrome-opening-new-era-for-rare-genetic-disorder 2025-04-26T22:34:18+00:00 hourly 0.9 https://trial.medpath.com/news/ema-recommends-approval-of-tepezza-for-thyroid-eye-disease-first-targeted-treatment-in-eu 2025-04-26T19:34:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-recommends-approval-of-tepezza-for-thyroid-eye-disease-first-targeted-treatment-in-eu 2025-04-26T19:34:25+00:00 hourly 0.9 https://trial.medpath.com/news/medtronic-s-hugo-robotic-surgery-system-meets-primary-endpoints-in-landmark-urologic-trial 2025-04-26T19:34:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medtronic-s-hugo-robotic-surgery-system-meets-primary-endpoints-in-landmark-urologic-trial 2025-04-26T19:34:23+00:00 hourly 0.9 https://trial.medpath.com/news/spyglass-pharma-s-iol-mounted-drug-delivery-platform-shows-promising-18-month-results-for-glaucoma-patients 2025-04-26T19:33:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spyglass-pharma-s-iol-mounted-drug-delivery-platform-shows-promising-18-month-results-for-glaucoma-patients 2025-04-26T19:33:44+00:00 hourly 0.9 https://trial.medpath.com/news/biocon-biologics-receives-positive-chmp-opinions-for-denosumab-biosimilars-in-europe 2025-04-26T16:34:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biocon-biologics-receives-positive-chmp-opinions-for-denosumab-biosimilars-in-europe 2025-04-26T16:34:21+00:00 hourly 0.9 https://trial.medpath.com/news/intensity-therapeutics-secures-2-35-million-in-public-offering-to-advance-cancer-immunotherapy-trials 2025-04-26T08:04:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/intensity-therapeutics-secures-2-35-million-in-public-offering-to-advance-cancer-immunotherapy-trials 2025-04-26T08:04:13+00:00 hourly 0.9 https://trial.medpath.com/news/city-of-hope-to-present-groundbreaking-cancer-research-at-aacr-annual-meeting-2025 2025-04-26T07:33:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/city-of-hope-to-present-groundbreaking-cancer-research-at-aacr-annual-meeting-2025 2025-04-26T07:33:26+00:00 hourly 0.9 https://trial.medpath.com/news/keymed-biosciences-advances-novel-cdh17-targeted-adc-for-gastrointestinal-cancers-with-ind-approval-in-china 2025-04-26T04:33:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/keymed-biosciences-advances-novel-cdh17-targeted-adc-for-gastrointestinal-cancers-with-ind-approval-in-china 2025-04-26T04:33:44+00:00 hourly 0.9 https://trial.medpath.com/news/nccn-updates-guidelines-to-recommend-dpyd-testing-before-fluoropyrimidine-chemotherapy 2025-04-26T03:03:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nccn-updates-guidelines-to-recommend-dpyd-testing-before-fluoropyrimidine-chemotherapy 2025-04-26T03:03:43+00:00 hourly 0.9 https://trial.medpath.com/news/study-reveals-age-specific-disease-burdens-in-pediatric-and-adolescent-atopic-dermatitis-patients 2025-04-26T03:03:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-reveals-age-specific-disease-burdens-in-pediatric-and-adolescent-atopic-dermatitis-patients 2025-04-26T03:03:26+00:00 hourly 0.9 https://trial.medpath.com/news/clinical-ink-launches-triallens-ai-powered-analytics-dashboard-transforms-clinical-trial-data-management 2025-04-26T02:33:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clinical-ink-launches-triallens-ai-powered-analytics-dashboard-transforms-clinical-trial-data-management 2025-04-26T02:33:22+00:00 hourly 0.9 https://trial.medpath.com/news/biohaven-withdraws-eu-application-for-troriluzole-in-spinocerebellar-ataxia-rbc-remains-optimistic 2025-04-26T02:06:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biohaven-withdraws-eu-application-for-troriluzole-in-spinocerebellar-ataxia-rbc-remains-optimistic 2025-04-26T02:06:47+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-medtronic-s-omniasecure-world-s-smallest-defibrillation-lead-for-cardiac-patients 2025-04-26T01:33:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-medtronic-s-omniasecure-world-s-smallest-defibrillation-lead-for-cardiac-patients 2025-04-26T01:33:34+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-medtech-reports-promising-3-month-data-for-omnypulse-platform-in-atrial-fibrillation-treatment 2025-04-26T01:33:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johnson-johnson-medtech-reports-promising-3-month-data-for-omnypulse-platform-in-atrial-fibrillation-treatment 2025-04-26T01:33:32+00:00 hourly 0.9 https://trial.medpath.com/news/proposed-25-pharmaceutical-tariffs-could-increase-us-drug-costs-by-51-billion-annually 2025-04-25T23:05:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/proposed-25-pharmaceutical-tariffs-could-increase-us-drug-costs-by-51-billion-annually 2025-04-25T23:05:55+00:00 hourly 0.9 https://trial.medpath.com/news/fda-requests-additional-trial-for-novavax-covid-19-vaccine-before-full-approval 2025-04-25T22:40:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-requests-additional-trial-for-novavax-covid-19-vaccine-before-full-approval 2025-04-25T22:40:26+00:00 hourly 0.9 https://trial.medpath.com/news/veracyte-expands-decipher-prostate-test-to-metastatic-cancer-patients-offering-new-treatment-guidance-tool 2025-04-25T22:39:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/veracyte-expands-decipher-prostate-test-to-metastatic-cancer-patients-offering-new-treatment-guidance-tool 2025-04-25T22:39:49+00:00 hourly 0.9 https://trial.medpath.com/news/myriad-genetics-precise-mrd-test-shows-promise-for-personalized-treatment-in-renal-cell-carcinoma 2025-04-25T22:39:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/myriad-genetics-precise-mrd-test-shows-promise-for-personalized-treatment-in-renal-cell-carcinoma 2025-04-25T22:39:33+00:00 hourly 0.9 https://trial.medpath.com/news/md-anderson-researchers-present-breakthrough-cancer-therapies-at-aacr-2025 2025-04-25T22:38:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/md-anderson-researchers-present-breakthrough-cancer-therapies-at-aacr-2025 2025-04-25T22:38:33+00:00 hourly 0.9 https://trial.medpath.com/news/aacr-annual-meeting-2025-to-bridge-gap-between-cancer-science-and-clinical-practice 2025-04-25T22:37:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aacr-annual-meeting-2025-to-bridge-gap-between-cancer-science-and-clinical-practice 2025-04-25T22:37:47+00:00 hourly 0.9 https://trial.medpath.com/news/billiontoone-to-showcase-advanced-liquid-biopsy-innovations-at-aacr-2025 2025-04-25T20:05:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/billiontoone-to-showcase-advanced-liquid-biopsy-innovations-at-aacr-2025 2025-04-25T20:05:27+00:00 hourly 0.9 https://trial.medpath.com/news/uk-court-of-appeal-grants-astrazeneca-interim-injunction-against-glenmark-s-generic-dapagliflozin 2025-04-25T20:04:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-court-of-appeal-grants-astrazeneca-interim-injunction-against-glenmark-s-generic-dapagliflozin 2025-04-25T20:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/nimbus-therapeutics-initiates-first-in-human-trial-of-ndi-219216-for-msi-h-tumors-resistant-to-standard-therapies 2025-04-25T19:37:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nimbus-therapeutics-initiates-first-in-human-trial-of-ndi-219216-for-msi-h-tumors-resistant-to-standard-therapies 2025-04-25T19:37:01+00:00 hourly 0.9 https://trial.medpath.com/news/leap-therapeutics-fl-501-shows-promise-in-reversing-cancer-cachexia-in-preclinical-studies 2025-04-25T19:37:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/leap-therapeutics-fl-501-shows-promise-in-reversing-cancer-cachexia-in-preclinical-studies 2025-04-25T19:37:00+00:00 hourly 0.9 https://trial.medpath.com/news/amgen-announces-900-million-manufacturing-expansion-in-ohio-creating-350-new-jobs 2025-04-25T19:36:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amgen-announces-900-million-manufacturing-expansion-in-ohio-creating-350-new-jobs 2025-04-25T19:36:52+00:00 hourly 0.9 https://trial.medpath.com/news/akeso-secures-fda-approval-for-novel-cancer-drug-while-partner-summit-therapeutics-faces-sharp-stock-decline 2025-04-25T19:36:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/akeso-secures-fda-approval-for-novel-cancer-drug-while-partner-summit-therapeutics-faces-sharp-stock-decline 2025-04-25T19:36:49+00:00 hourly 0.9 https://trial.medpath.com/news/dana-farber-researchers-present-breakthrough-cancer-studies-at-aacr-2025-annual-meeting 2025-04-25T19:36:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dana-farber-researchers-present-breakthrough-cancer-studies-at-aacr-2025-annual-meeting 2025-04-25T19:36:22+00:00 hourly 0.9 https://trial.medpath.com/news/smart-drug-delivery-systems-market-poised-for-17-growth-as-chronic-disease-management-evolves 2025-04-25T19:36:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/smart-drug-delivery-systems-market-poised-for-17-growth-as-chronic-disease-management-evolves 2025-04-25T19:36:10+00:00 hourly 0.9 https://trial.medpath.com/news/biohaven-withdraws-eu-application-for-spinocerebellar-ataxia-drug-dazluma 2025-04-25T19:36:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biohaven-withdraws-eu-application-for-spinocerebellar-ataxia-drug-dazluma 2025-04-25T19:36:04+00:00 hourly 0.9 https://trial.medpath.com/news/emercell-receives-ema-approval-to-study-allogeneic-nk-cell-therapy-for-diffuse-large-b-cell-lymphoma 2025-04-25T19:36:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/emercell-receives-ema-approval-to-study-allogeneic-nk-cell-therapy-for-diffuse-large-b-cell-lymphoma 2025-04-25T19:36:01+00:00 hourly 0.9 https://trial.medpath.com/news/ema-s-role-in-regulatory-reliance-for-post-approval-changes 2025-04-25T19:35:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-s-role-in-regulatory-reliance-for-post-approval-changes 2025-04-25T19:35:35+00:00 hourly 0.9 https://trial.medpath.com/news/uk-court-of-appeal-grants-astrazeneca-injunction-against-glenmark-s-diabetes-generic 2025-04-25T19:35:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-court-of-appeal-grants-astrazeneca-injunction-against-glenmark-s-diabetes-generic 2025-04-25T19:35:26+00:00 hourly 0.9 https://trial.medpath.com/news/suven-pharmaceuticals-and-cohance-lifesciences-merger-approved-creating-1-billion-cdmo-powerhouse 2025-04-25T19:35:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/suven-pharmaceuticals-and-cohance-lifesciences-merger-approved-creating-1-billion-cdmo-powerhouse 2025-04-25T19:35:20+00:00 hourly 0.9 https://trial.medpath.com/news/olema-s-kat6-inhibitor-op-3136-shows-promising-anti-tumor-activity-across-multiple-cancer-types 2025-04-25T19:33:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/olema-s-kat6-inhibitor-op-3136-shows-promising-anti-tumor-activity-across-multiple-cancer-types 2025-04-25T19:33:38+00:00 hourly 0.9 https://trial.medpath.com/news/pneumonia-antibiotic-piperacillin-shows-promise-as-targeted-lyme-disease-treatment-at-100-fold-lower-doses 2025-04-25T18:23:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pneumonia-antibiotic-piperacillin-shows-promise-as-targeted-lyme-disease-treatment-at-100-fold-lower-doses 2025-04-25T18:23:12+00:00 hourly 0.9 https://trial.medpath.com/news/lupin-limited-sets-new-benchmark-with-india-s-largest-diabetes-real-world-evidence-study 2025-04-25T17:37:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lupin-limited-sets-new-benchmark-with-india-s-largest-diabetes-real-world-evidence-study 2025-04-25T17:37:50+00:00 hourly 0.9 https://trial.medpath.com/news/alx-oncology-s-cd47-inhibitor-combination-with-keytruda-fails-in-dual-phase-ii-trials 2025-04-25T17:04:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alx-oncology-s-cd47-inhibitor-combination-with-keytruda-fails-in-dual-phase-ii-trials 2025-04-25T17:04:18+00:00 hourly 0.9 https://trial.medpath.com/news/catalym-s-visugromab-shows-promise-in-enhancing-antibody-drug-conjugate-efficacy-by-blocking-gdf-15 2025-04-25T17:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/catalym-s-visugromab-shows-promise-in-enhancing-antibody-drug-conjugate-efficacy-by-blocking-gdf-15 2025-04-25T17:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cdr-life-s-novel-t-cell-engagers-show-superior-potency-against-solid-tumors-in-preclinical-studies 2025-04-25T17:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cdr-life-s-novel-t-cell-engagers-show-superior-potency-against-solid-tumors-in-preclinical-studies 2025-04-25T17:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/vivavision-s-vvn461-shows-promising-results-in-phase-2-trial-for-non-infectious-anterior-uveitis 2025-04-25T16:36:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vivavision-s-vvn461-shows-promising-results-in-phase-2-trial-for-non-infectious-anterior-uveitis 2025-04-25T16:36:55+00:00 hourly 0.9 https://trial.medpath.com/news/chmp-recommends-approval-of-oczyesa-for-acromegaly-treatment-in-the-eu 2025-04-25T16:35:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chmp-recommends-approval-of-oczyesa-for-acromegaly-treatment-in-the-eu 2025-04-25T16:35:58+00:00 hourly 0.9 https://trial.medpath.com/news/ptc-therapeutics-sephience-receives-positive-chmp-opinion-for-phenylketonuria-treatment-across-all-age-groups 2025-04-25T16:35:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ptc-therapeutics-sephience-receives-positive-chmp-opinion-for-phenylketonuria-treatment-across-all-age-groups 2025-04-25T16:35:57+00:00 hourly 0.9 https://trial.medpath.com/news/global-clinical-trial-launches-to-test-sipavibart-as-potential-long-covid-treatment 2025-04-25T16:35:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-clinical-trial-launches-to-test-sipavibart-as-potential-long-covid-treatment 2025-04-25T16:35:42+00:00 hourly 0.9 https://trial.medpath.com/news/caribou-biosciences-restructures-abandons-autoimmune-program-to-focus-on-cancer-cell-therapies 2025-04-25T16:35:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/caribou-biosciences-restructures-abandons-autoimmune-program-to-focus-on-cancer-cell-therapies 2025-04-25T16:35:41+00:00 hourly 0.9 https://trial.medpath.com/news/evorpacept-keytruda-combination-fails-to-meet-primary-endpoints-in-head-and-neck-cancer-trials 2025-04-25T16:35:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evorpacept-keytruda-combination-fails-to-meet-primary-endpoints-in-head-and-neck-cancer-trials 2025-04-25T16:35:39+00:00 hourly 0.9 https://trial.medpath.com/news/queen-elizabeth-hospital-leads-uk-recruitment-in-global-astrazeneca-heart-failure-trial 2025-04-25T16:33:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/queen-elizabeth-hospital-leads-uk-recruitment-in-global-astrazeneca-heart-failure-trial 2025-04-25T16:33:54+00:00 hourly 0.9 https://trial.medpath.com/news/clearb-therapeutics-to-present-promising-preclinical-data-on-hepatitis-b-therapeutic-vaccine-at-easl-2025 2025-04-25T16:07:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clearb-therapeutics-to-present-promising-preclinical-data-on-hepatitis-b-therapeutic-vaccine-at-easl-2025 2025-04-25T16:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/caredx-showcases-extensive-clinical-evidence-for-transplant-monitoring-solutions-at-ishlt-2025 2025-04-25T13:34:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/caredx-showcases-extensive-clinical-evidence-for-transplant-monitoring-solutions-at-ishlt-2025 2025-04-25T13:34:44+00:00 hourly 0.9 https://trial.medpath.com/news/genfit-reports-strong-2024-financial-results-with-first-commercial-revenues-from-iqirvo-r 2025-04-25T11:03:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genfit-reports-strong-2024-financial-results-with-first-commercial-revenues-from-iqirvo-r 2025-04-25T11:03:35+00:00 hourly 0.9 https://trial.medpath.com/news/hansa-biopharma-appoints-renee-aguiar-lucander-as-new-ceo-marking-new-growth-phase 2025-04-25T10:33:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hansa-biopharma-appoints-renee-aguiar-lucander-as-new-ceo-marking-new-growth-phase 2025-04-25T10:33:36+00:00 hourly 0.9 https://trial.medpath.com/news/nordic-pharma-launches-authorized-generic-of-maxitrol-for-bacterial-eye-infections 2025-04-25T10:33:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nordic-pharma-launches-authorized-generic-of-maxitrol-for-bacterial-eye-infections 2025-04-25T10:33:29+00:00 hourly 0.9 https://trial.medpath.com/news/syncromune-to-present-phase-1-data-on-novel-sync-t-therapy-for-metastatic-prostate-cancer-at-asco-2025 2025-04-25T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/syncromune-to-present-phase-1-data-on-novel-sync-t-therapy-for-metastatic-prostate-cancer-at-asco-2025 2025-04-25T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-circa-scientific-s-pericrosstm-epicardial-access-kit-with-100-success-rate-in-clinical-trial 2025-04-25T04:20:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-circa-scientific-s-pericrosstm-epicardial-access-kit-with-100-success-rate-in-clinical-trial 2025-04-25T04:20:12+00:00 hourly 0.9 https://trial.medpath.com/news/allarity-therapeutics-unveils-novel-predictive-tool-for-daratumumab-response-in-multiple-myeloma-patients 2025-04-25T02:42:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/allarity-therapeutics-unveils-novel-predictive-tool-for-daratumumab-response-in-multiple-myeloma-patients 2025-04-25T02:42:00+00:00 hourly 0.9 https://trial.medpath.com/news/pipeline-analysis-reveals-20-therapies-in-development-for-open-angle-glaucoma-treatment 2025-04-25T01:34:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pipeline-analysis-reveals-20-therapies-in-development-for-open-angle-glaucoma-treatment 2025-04-25T01:34:44+00:00 hourly 0.9 https://trial.medpath.com/news/avidicure-launches-with-50m-to-develop-novel-multifunctional-antibody-platform-for-cancer 2025-04-25T01:34:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avidicure-launches-with-50m-to-develop-novel-multifunctional-antibody-platform-for-cancer 2025-04-25T01:34:01+00:00 hourly 0.9 https://trial.medpath.com/news/bpgbio-s-bpm31510-demonstrates-breakthrough-blood-brain-barrier-penetration-for-mitochondrial-disease-treatment 2025-04-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bpgbio-s-bpm31510-demonstrates-breakthrough-blood-brain-barrier-penetration-for-mitochondrial-disease-treatment 2025-04-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cn-bio-and-pharmaron-partner-to-advance-organ-on-a-chip-technology-for-drug-development 2025-04-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cn-bio-and-pharmaron-partner-to-advance-organ-on-a-chip-technology-for-drug-development 2025-04-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/avvio-medical-to-present-novel-urological-device-trial-results-at-2025-aua-annual-meeting 2025-04-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avvio-medical-to-present-novel-urological-device-trial-results-at-2025-aua-annual-meeting 2025-04-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/briacell-therapeutics-completes-13-8-million-public-offering-to-advance-cancer-immunotherapy-pipeline 2025-04-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/briacell-therapeutics-completes-13-8-million-public-offering-to-advance-cancer-immunotherapy-pipeline 2025-04-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/grove-biopharma-secures-30m-funding-expands-to-new-r-d-facility-in-chicago-s-fulton-market 2025-04-24T23:45:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/grove-biopharma-secures-30m-funding-expands-to-new-r-d-facility-in-chicago-s-fulton-market 2025-04-24T23:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/circle-pharma-to-reveal-dual-mechanism-of-novel-cyclin-a-b-rxl-inhibitors-at-aacr-2025 2025-04-24T23:36:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/circle-pharma-to-reveal-dual-mechanism-of-novel-cyclin-a-b-rxl-inhibitors-at-aacr-2025 2025-04-24T23:36:24+00:00 hourly 0.9 https://trial.medpath.com/news/montana-pioneers-experimental-treatment-hub-with-new-legislation-expanding-right-to-try 2025-04-24T23:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/montana-pioneers-experimental-treatment-hub-with-new-legislation-expanding-right-to-try 2025-04-24T23:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/lumicera-and-costco-partner-to-expand-cost-plus-specialty-pharmacy-services-for-chronic-and-rare-conditions 2025-04-24T22:36:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lumicera-and-costco-partner-to-expand-cost-plus-specialty-pharmacy-services-for-chronic-and-rare-conditions 2025-04-24T22:36:46+00:00 hourly 0.9 https://trial.medpath.com/news/araceli-biosciences-secures-11-2m-seed-funding-to-accelerate-ai-powered-drug-discovery-imaging 2025-04-24T22:34:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/araceli-biosciences-secures-11-2m-seed-funding-to-accelerate-ai-powered-drug-discovery-imaging 2025-04-24T22:34:51+00:00 hourly 0.9 https://trial.medpath.com/news/corwave-s-novel-lvad-shows-promising-results-in-6-month-preclinical-study-advancing-to-human-trials 2025-04-24T22:33:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/corwave-s-novel-lvad-shows-promising-results-in-6-month-preclinical-study-advancing-to-human-trials 2025-04-24T22:33:53+00:00 hourly 0.9 https://trial.medpath.com/news/biocon-launches-4500-crore-qip-to-strengthen-balance-sheet-and-reduce-debt 2025-04-24T21:50:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biocon-launches-4500-crore-qip-to-strengthen-balance-sheet-and-reduce-debt 2025-04-24T21:50:00+00:00 hourly 0.9 https://trial.medpath.com/news/guardant-health-and-pfizer-form-strategic-alliance-to-advance-cancer-therapies-using-liquid-biopsy-technology 2025-04-24T20:04:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/guardant-health-and-pfizer-form-strategic-alliance-to-advance-cancer-therapies-using-liquid-biopsy-technology 2025-04-24T20:04:16+00:00 hourly 0.9 https://trial.medpath.com/news/topas-therapeutics-to-present-promising-phase-2a-data-for-novel-celiac-disease-treatment-at-ddw-2025 2025-04-24T20:04:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/topas-therapeutics-to-present-promising-phase-2a-data-for-novel-celiac-disease-treatment-at-ddw-2025 2025-04-24T20:04:11+00:00 hourly 0.9 https://trial.medpath.com/news/mosaic-therapeutics-acquires-two-clinical-stage-oncology-programs-from-astex-to-develop-novel-combination-therapies 2025-04-24T19:34:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mosaic-therapeutics-acquires-two-clinical-stage-oncology-programs-from-astex-to-develop-novel-combination-therapies 2025-04-24T19:34:54+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-seeks-fda-approval-for-novel-serotype-e-botulinum-neurotoxin-for-glabellar-lines 2025-04-24T19:34:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-seeks-fda-approval-for-novel-serotype-e-botulinum-neurotoxin-for-glabellar-lines 2025-04-24T19:34:53+00:00 hourly 0.9 https://trial.medpath.com/news/amplifier-health-and-xeomics-partner-to-advance-voice-based-diagnostic-ai-with-750000-global-voice-samples 2025-04-24T19:34:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amplifier-health-and-xeomics-partner-to-advance-voice-based-diagnostic-ai-with-750000-global-voice-samples 2025-04-24T19:34:48+00:00 hourly 0.9 https://trial.medpath.com/news/arrowhead-s-plozasiran-for-familial-chylomicronemia-syndrome-fast-tracked-for-eu-approval 2025-04-24T19:34:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arrowhead-s-plozasiran-for-familial-chylomicronemia-syndrome-fast-tracked-for-eu-approval 2025-04-24T19:34:45+00:00 hourly 0.9 https://trial.medpath.com/news/medtronic-submits-interoperable-insulin-pump-to-fda-advancing-abbott-partnership 2025-04-24T19:34:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medtronic-submits-interoperable-insulin-pump-to-fda-advancing-abbott-partnership 2025-04-24T19:34:38+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-halts-balinatunfib-monotherapy-development-after-phase-ii-psoriasis-trial-miss 2025-04-24T19:34:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-halts-balinatunfib-monotherapy-development-after-phase-ii-psoriasis-trial-miss 2025-04-24T19:34:00+00:00 hourly 0.9 https://trial.medpath.com/news/sarcopenia-pipeline-shows-robust-growth-with-18-pharma-companies-developing-novel-therapies 2025-04-24T18:25:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sarcopenia-pipeline-shows-robust-growth-with-18-pharma-companies-developing-novel-therapies 2025-04-24T18:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/cytoagents-advances-phase-1b-2a-trial-of-cto1681-for-cytokine-release-syndrome-in-car-t-cell-therapy-patients 2025-04-24T17:33:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cytoagents-advances-phase-1b-2a-trial-of-cto1681-for-cytokine-release-syndrome-in-car-t-cell-therapy-patients 2025-04-24T17:33:58+00:00 hourly 0.9 https://trial.medpath.com/news/dt-109-novel-glycine-based-compound-shows-dual-efficacy-against-atherosclerosis-and-mash 2025-04-24T17:33:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dt-109-novel-glycine-based-compound-shows-dual-efficacy-against-atherosclerosis-and-mash 2025-04-24T17:33:21+00:00 hourly 0.9 https://trial.medpath.com/news/promising-alzheimer-s-vaccine-targeting-tau-protein-advances-toward-human-trials 2025-04-24T17:07:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/promising-alzheimer-s-vaccine-targeting-tau-protein-advances-toward-human-trials 2025-04-24T17:07:17+00:00 hourly 0.9 https://trial.medpath.com/news/fda-sets-q3-2025-approval-dates-for-three-breakthrough-therapies-targeting-rare-diseases 2025-04-24T17:05:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-sets-q3-2025-approval-dates-for-three-breakthrough-therapies-targeting-rare-diseases 2025-04-24T17:05:55+00:00 hourly 0.9 https://trial.medpath.com/news/india-conducts-first-human-gene-therapy-trial-for-hemophilia-in-landmark-collaboration 2025-04-24T16:37:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-conducts-first-human-gene-therapy-trial-for-hemophilia-in-landmark-collaboration 2025-04-24T16:37:51+00:00 hourly 0.9 https://trial.medpath.com/news/veraxa-biotech-and-voyager-acquisition-to-merge-creating-1-64b-nasdaq-listed-cancer-therapeutics-company 2025-04-24T16:37:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/veraxa-biotech-and-voyager-acquisition-to-merge-creating-1-64b-nasdaq-listed-cancer-therapeutics-company 2025-04-24T16:37:23+00:00 hourly 0.9 https://trial.medpath.com/news/renibus-completes-enrollment-in-pivotal-phase-3-protect-trial-of-rbt-1-for-cardiac-surgery-complications 2025-04-24T16:37:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/renibus-completes-enrollment-in-pivotal-phase-3-protect-trial-of-rbt-1-for-cardiac-surgery-complications 2025-04-24T16:37:22+00:00 hourly 0.9 https://trial.medpath.com/news/entod-pharmaceuticals-receives-first-global-approval-for-0-05-atropine-eye-drops-to-combat-childhood-myopia 2025-04-24T16:37:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/entod-pharmaceuticals-receives-first-global-approval-for-0-05-atropine-eye-drops-to-combat-childhood-myopia 2025-04-24T16:37:20+00:00 hourly 0.9 https://trial.medpath.com/news/liverpool-researchers-trial-oral-treatment-for-deadly-leishmaniasis-disease 2025-04-24T16:36:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/liverpool-researchers-trial-oral-treatment-for-deadly-leishmaniasis-disease 2025-04-24T16:36:05+00:00 hourly 0.9 https://trial.medpath.com/news/cocrystal-pharma-s-antiviral-cdi-988-shows-potent-activity-against-emerging-norovirus-variants 2025-04-24T16:35:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cocrystal-pharma-s-antiviral-cdi-988-shows-potent-activity-against-emerging-norovirus-variants 2025-04-24T16:35:59+00:00 hourly 0.9 https://trial.medpath.com/news/ireland-launches-magic-i-first-national-genomics-study-to-transform-childhood-cancer-care 2025-04-24T16:35:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ireland-launches-magic-i-first-national-genomics-study-to-transform-childhood-cancer-care 2025-04-24T16:35:58+00:00 hourly 0.9 https://trial.medpath.com/news/vir-biotechnology-to-present-key-hepatitis-b-and-delta-clinical-data-at-easl-congress-2025 2025-04-24T16:35:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vir-biotechnology-to-present-key-hepatitis-b-and-delta-clinical-data-at-easl-congress-2025 2025-04-24T16:35:22+00:00 hourly 0.9 https://trial.medpath.com/news/seed-therapeutics-advances-dual-breakthrough-programs-in-targeted-protein-degradation-at-aacr-2025 2025-04-24T16:35:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/seed-therapeutics-advances-dual-breakthrough-programs-in-targeted-protein-degradation-at-aacr-2025 2025-04-24T16:35:19+00:00 hourly 0.9 https://trial.medpath.com/news/akoya-biosciences-launches-advanced-adc-breast-cancer-assay-for-precision-oncology 2025-04-24T16:35:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/akoya-biosciences-launches-advanced-adc-breast-cancer-assay-for-precision-oncology 2025-04-24T16:35:03+00:00 hourly 0.9 https://trial.medpath.com/news/granite-bio-emerges-with-100m-funding-and-novel-immunology-pipeline-for-ibd-and-allergies 2025-04-24T16:35:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/granite-bio-emerges-with-100m-funding-and-novel-immunology-pipeline-for-ibd-and-allergies 2025-04-24T16:35:02+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-ferring-pharmaceuticals-new-manufacturing-facility-for-bladder-cancer-gene-therapy-adstiladrin 2025-04-24T16:34:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-ferring-pharmaceuticals-new-manufacturing-facility-for-bladder-cancer-gene-therapy-adstiladrin 2025-04-24T16:34:24+00:00 hourly 0.9 https://trial.medpath.com/news/inhalerx-secures-38-5-million-funding-to-advance-novel-inhaled-therapies-for-cancer-pain-and-panic-disorder 2025-04-24T16:33:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inhalerx-secures-38-5-million-funding-to-advance-novel-inhaled-therapies-for-cancer-pain-and-panic-disorder 2025-04-24T16:33:54+00:00 hourly 0.9 https://trial.medpath.com/news/novel-non-hormonal-male-contraceptive-adam-shows-two-year-efficacy-in-clinical-trials 2025-04-24T16:33:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-non-hormonal-male-contraceptive-adam-shows-two-year-efficacy-in-clinical-trials 2025-04-24T16:33:53+00:00 hourly 0.9 https://trial.medpath.com/news/koelis-and-bot-image-partner-to-enhance-prostate-cancer-detection-with-ai-powered-fusion-biopsy-technology 2025-04-24T16:22:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/koelis-and-bot-image-partner-to-enhance-prostate-cancer-detection-with-ai-powered-fusion-biopsy-technology 2025-04-24T16:22:00+00:00 hourly 0.9 https://trial.medpath.com/news/cell-therapy-advances-show-promise-for-hepatocellular-carcinoma-treatment 2025-04-24T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cell-therapy-advances-show-promise-for-hepatocellular-carcinoma-treatment 2025-04-24T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/varenicline-shows-promising-results-for-youth-vaping-cessation-in-landmark-trial 2025-04-24T14:03:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/varenicline-shows-promising-results-for-youth-vaping-cessation-in-landmark-trial 2025-04-24T14:03:25+00:00 hourly 0.9 https://trial.medpath.com/news/boston-scientific-s-farapulse-pfa-system-shows-promising-results-for-persistent-atrial-fibrillation-treatment 2025-04-24T13:44:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/boston-scientific-s-farapulse-pfa-system-shows-promising-results-for-persistent-atrial-fibrillation-treatment 2025-04-24T13:44:00+00:00 hourly 0.9 https://trial.medpath.com/news/single-dose-baloxavir-significantly-reduces-household-influenza-transmission-in-global-phase-iii-trial 2025-04-24T13:36:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/single-dose-baloxavir-significantly-reduces-household-influenza-transmission-in-global-phase-iii-trial 2025-04-24T13:36:09+00:00 hourly 0.9 https://trial.medpath.com/news/promising-pipeline-for-mantle-cell-lymphoma-treatment-22-therapies-under-development-by-20-companies 2025-04-24T13:36:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/promising-pipeline-for-mantle-cell-lymphoma-treatment-22-therapies-under-development-by-20-companies 2025-04-24T13:36:01+00:00 hourly 0.9 https://trial.medpath.com/news/etiome-emerges-with-50m-to-target-disease-biomarkers-before-symptoms-appear 2025-04-24T13:36:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/etiome-emerges-with-50m-to-target-disease-biomarkers-before-symptoms-appear 2025-04-24T13:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/summit-s-ivonescimab-shows-promise-in-phase-iii-trial-against-established-lung-cancer-therapies 2025-04-24T13:35:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/summit-s-ivonescimab-shows-promise-in-phase-iii-trial-against-established-lung-cancer-therapies 2025-04-24T13:35:54+00:00 hourly 0.9 https://trial.medpath.com/news/geovax-s-multi-antigen-covid-19-vaccine-shows-promising-results-in-immunocompromised-patients 2025-04-24T11:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/geovax-s-multi-antigen-covid-19-vaccine-shows-promising-results-in-immunocompromised-patients 2025-04-24T11:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/medit-and-graphy-form-strategic-alliance-to-transform-digital-orthodontics-with-3d-printed-clear-aligners 2025-04-24T11:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medit-and-graphy-form-strategic-alliance-to-transform-digital-orthodontics-with-3d-printed-clear-aligners 2025-04-24T11:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/hydrogel-coated-membranes-reduce-t-cell-exhaustion-in-car-t-manufacturing 2025-04-24T11:05:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hydrogel-coated-membranes-reduce-t-cell-exhaustion-in-car-t-manufacturing 2025-04-24T11:05:57+00:00 hourly 0.9